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ABSTRACT  
Background: The point-of-care platelet function test Plateletworks® has been shown to identify patients with 
high platelet aggregation despite P2Y12 inhibition, also known as high-on-treatment platelet reactivity (HPR), 
who have increased risk for ischemic cardiovascular events. However, this platelet function assay has not been 
sufficiently validated. Patients who instead have excessive platelet inhibition are at risk for bleeding but 
predictive value of the Plateletworks® assay regarding bleeding has not been shown. Clopidogrel is today largely 
replaced by newer P2Y12 inhibitors such as ticagrelor due to improved outcome. The drug uptake after a 180 mg 
loading dose (LD) of ticagrelor has, however, not been thoroughly investigated in patients with non ST-segment 
elevation myocardial infarction (NSTEMI). Patients with ST-segment elevation myocardial infarction (STEMI) 
have a slower uptake of ticagrelor, likely due to morphine-induced inhibition of gastrointestinal motility. 
Aims I: To identify patients pretreated with clopidogrel at increased risk for adverse clinical events after 
coronary angiography; II: To investigate the relation between platelet reactivity and the 30-day incidence of 
bleeding complications, as defined by two relevant bleeding definitions in clopidogrel-treated patients; III: To 
evaluate the ticagrelor uptake and platelet P2Y12 inhibition in patients with NSTEMI not receiving opioids and 
compare these data with those of patients with stable coronary artery disease (SCAD); IV: To evaluate if the 
peripheral opioid antagonist methylnaltrexone could improve platelet inhibition after a LD of 180 mg ticagrelor 
in morphine treated patients with STEMI. 
Methods: Study I and II were observational, prospective studies based on the same cohort of 491 patients on 
clopidogrel who underwent coronary angiography. Platelet aggregation was measured with adenosine 
diphosphate-induced platelet function testing (Plateletworks®) and a cut-off was established for prediction of the 
respective primary outcome variable.  In Study I, Patients were followed for three months, and the primary 
endpoint was myocardial infarction. In Study II, the primary endpoint was incidence of bleeding within 30 days 
as defined by the BARC and ARMYDA-BLEEDS bleeding definitions. Study III was an observational, 
prospective study on 40 NSTEMI patients and 20 controls. Both groups received a 180 mg ticagrelor LD and 
blood samples were taken pre-dose and 1, 2, 3, 4, 5, and 6 hours post LD.  Plasma concentrations of ticagrelor 
and its active metabolite AR-C124910XX were analyzed as well as platelet inhibition. The primary endpoint 
was the time to maximal ticagrelor concentration (Tmax). Study IV was a multicenter, prospective, randomized, 
controlled trial in STEMI patients treated with morphine and ticagrelor. Patients were randomized to a blinded 
intravenous injection of either methylnaltrexone or 0.9% sodium chloride. The proportion of patients with HPR 
and the plasma concentrations of ticagrelor and AR-C124910XX were assessed at baseline, one, and two hours. 
Results I: A cut-off of 82.3% platelet aggregation was found to predict myocardial infarction and thus defined 
HPR. In total 39.9% (n=196/491) had HPR. At three months follow-up the event rates of myocardial infarction 
(MI) and rehospitalization, respectively, were higher in patients with HPR (5.1% vs. 1.7%, p=0.03; and 23.0% 
vs. 14.2%, p=0.01, respectively). II: In total, 474 patients of the initial cohort of 491 were included. Patients in 
the lowest platelet aggregation quartile had a higher frequency of ≥type 2 BARC bleeding and ARMYDA-
BLEEDS defined bleeding within 30 days compared with the highest quartile (16.9% vs. 6.7%, p=0.014, and 
8.5% vs. 1.7%, p=0.016, respectively). III: The Tmax of ticagrelor did not significantly differ between NSTEMI 
patients and the controls (2.0h [1.0-3.0]) vs. 2.0h [2.0-3.0], p=0.393). HPR was at one hour seen in 15% of the 
NSTEMI patients versus 10% of the controls (p=1.0) and at two hours in 3% of the NSTEMI patients compared 
with none of the controls (p=1.0). IV: A total of 82 patients received either methylnaltrexone (n=43) or placebo 
(n= 39). Methylnaltrexone administration did not significantly affect prevalence of HPR at two hours after 
inclusion, the primary end-point, compared with placebo (54% vs. 51%, p=0.84). Plasma concentrations of 
ticagrelor and its active metabolite did not differ significantly between the groups over time. 
Conclusions I: Testing with Plateletworks® identified patients at increased risk of myocardial infarction and 
rehospitalization within three months after coronary angiography. II: Patients in the lowest platelet aggregation 
quartile had a significantly higher incidence of bleeding according to BARC and ARMYDA-BLEEDS 
definitions within 30 days III: The uptake of ticagrelor was not significantly slower in NSTEMI patients 
compared with the SCAD controls with adequate onset of platelet inhibition in both groups. IV: 
Methylnaltrexone did not significantly improve platelet reactivity or plasma concentrations of orally 
administered ticagrelor in STEMI patients receiving morphine.  
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Bakgrund och syfte: I samband med undersökning av hjärtats kranskärl respektive ballongvidgning och 
stentbehandling av förträngningar i kranskärlen behandlas patienter rutinmässigt med läkemedel som hämmar 
blodplättarnas förmåga att klibba ihop sig. Tidigare studier har visat att dessa blodplättshämmande läkemedel 
även minskar risken för blodproppsbildning i kranskärlen och andra pulsådror och därmed minskar risken för 
komplikationer i samband med och efter kranskärlsundersökningen/behandlingen. Under lång tid har det 
blodplättshämmande läkemedlet acetylsalicylsyra (Trombyl®, Bamyl®, etc) utgjort grunden i behandlingen av 
patienter med kranskärlssjukdom. Senare studier har dock visat att ”dubbel blodplättshämning” med tillägg av 
läkemedlet klopidogrel (Plavix®) ytterligare minskar komplikationsrisken varför denna kombinationsbehandling 
sedan millennieskiftet rutinmässigt använts. Det har dock framkommit att en standarddos av klopidogrel hos en 
del av patienterna inte alltid ger den förväntade hämningen av blodplättarna och att dessa patienter därmed har 
en ökning av risken för blodproppar och insjuknande i hjärt-kärlsjukdom. Graden av blodplättshämning efter en 
standarddos av klopidogrel går dock att mäta med analysmetoder som är olika väl studerade. Studie I syftade till 
att med en enkel men relativt undermåligt utvärderad mätmetod (Plateletworks®) mäta graden av hämning hos 
blodplättarna efter en standarddos klopidogrel hos patienter som genomgick kranskärlsundersökningen och 
behandling samt att följa upp ifall analysresultaten kunde förutse återinsjuknande i hjärtinfarkt och annan hjärt-
kärlsjukdom inom tre månader. 
Patienter med pågående behandling med läkemedel som påverkar blodets förmåga att levra sig (koagulera), 
inklusive blodplättshämmande läkemedel, löper en ökad risk att drabbas av blödningar. Risken ökar med högre 
grad av hämning, vilket även funktionsanalyser kan påvisa.  Studie II utgick från samma patientgrupp som 
Studie I, men syftade istället till att utvärdera om analys med Plateletworks® kunde identifiera de patienter som 
fick blödningskomplikationer inom 30 dagar efter kranskärlsröntgen. Eftersom frekvensen av blödningar är 
väldigt beroende av vilka definitioner som används för att definiera vad som ska räknas som blödning använde 
vi i Studie II två olika blödningsdefinitioner, inklusive en relativ nyligen etablerad standardiserad 
blödningsdefinition.  
Hos patienter med akut och instabil kranskärlssjukdom inklusive hjärtinfarkt har klopidogrel på senare år i hög 
grad ersatts av nya blodplättshämmande läkemedel såsom tikagrelor (Brilique®) i tillägg till acetylsalicylsyra då 
dessa nyare hämmare har ett snabbare anslag och är mer potenta vilket har visat sig ytterligare minska risken för 
komplikationer jämfört med dubbel blodplättshämning med klopidogrel och acetylsalicylsyra. Tidigare studier 
har dock antytt att en standarddos tikagrelor hos vissa patienter inte alltid ger en rask hämning av blodplättarna, 
vilket skulle kunna medföra ett sämre skydd mot blodproppar. Studie III syftade till att i en undergrupp av 
hjärtinfarktpatienter med “icke ST-höjningsinfarkt”, så kallad NSTEMI, studera tiden det tog för den högsta 
läkemedelskoncentrationen tikagrelor att uppnås i blodet och att jämföra resultaten med läkemedelsupptagen hos 
patienter med stabil kranskärlssjukdom.  
Patienter med den mest utbredda formen av hjärtinfarkt (ST-höjningsinfarkt; STEMI) erhåller ofta redan i 
ambulansen rutinmässigt en laddningsdos tikagrelor i tablettform för att få en snabbt insättande hämning av 
blodplättarna inför kranskärlsundersökning och behandling. Denna patientgrupp får i ambulansen ofta även 
smärtstillande behandling med morfin. Studier antyder dock att morfinets negativa påverkan på mag-
tarmkanalens motorik och rörlighet orsakar ett försämrat läkemedelsupptag och minskar tidig effekt av 
tikagrelor, vilket skulle kunna medföra ökad risk för kliniska komplikationer. Läkemedlet metylnaltrexon 
(Relistor®) skulle möjligen kunna förbättra upptaget av tikagrelor då det motverkar morfineffekten i mag-
tarmkanalen utan att ta bort den smärtlindrande centrala effekten.  Studie IV syftade till att utvärdera detta hos 
patienter med STEMI som lottades (randomiserades) efter samtycke till metylnatrexon eller verkningslöst 
placebo och därefter mättes tiden det tog till att uppnå god effekt av läkemedlet tikagrelor.  
Metod: Studie I och II baserades båda på samma grupp av 491 patienter som alla erhöll behandling med 
klopidogrel och acetylsalicylsyra inför kranskärlsundersökning och behandling. Blodplättarnas hämning av 
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klopidogrel mättes med Plateletworks®. I studie I följdes patienterna med avseende på eventuellt insjuknande i 
hjärtinfarkt inom tre månader från och med att patienterna kom med i studien. Studie II inkluderade totalt 474 
av de ursprungliga 491 patienterna och dessa följdes med avseende på blödningshändelser inom 30 dagar från att 
de kom med i studien. Studie III inkluderade totalt 40 NSTEMI patienter och 20 kontrollpatienter med stabil 
kranskärlssjukdom. Båda grupperna erhöll en standarddos av 180 mg tikagrelor och blodprover togs för att mäta 
läkemedelsupptaget och blodplättshämningen just innan tikagrelordosen, samt vid varje timme under 6 timmar 
efteråt för att upptäcka en eventuell skillnad i tiden det tog till att uppnå maximal tikagrelorkoncentration. Studie 
IV inkluderade totalt 82 patienter med ST-höjningsinfarkt, som alla behandlats med morfin och tikagrelor. 
Lottning (randomisering) gjordes mellan metylnaltrexon eller placebo (koksalt), som gavs direkt i blodet och 
läkemedelsupptaget och blodplättshämningen mättes då respektive patient kom med i studien och efter en och 
två timmar. 
Resultat och slutsats I: Testning av blodplättsfunktionen med Plateletworks® identifierade patienter med 
undermålig behandlingseffekt av klopidogrel och denna grupp, som utgjorde 39,9% av de 491 inkluderade 
patienterna, drabbades i signifikant högre grad av en hjärtinfarkt inom tre månader jämfört med de patienter som 
hade god effekt av klopidogrel. II. De 474 patienterna delades in i fyra grupper (kvartiler) baserat på graden av 
blodplättshämning av klopidogrel som analyserades med Plateletworks®. Patienter i kvartilen med högst 
hämningsgrad drabbades i signifikant högre utsträckning av blödningskomplikationer inom 30 dagar efter 
kranskärlsröntgen jämfört med den kvartil som hade minst blodplättshämmande effekt av klopidogrel, oavsett 
vilken blödningsdefinition som användes. III. Tiden att uppnå maximal läkemedelskoncentration av tikagrelor 
skiljde sig inte mellan patienter med NSTEMI jämfört med patienter med stabil kranskärlssjukdom och inom två 
timmar hade nästan alla patienter i båda grupperna en tillräckligt hög blodplättshämning. Således var upptaget 
och läkemedelseffekten bra i båda grupperna. IV: De 43 patienter som lottades till metylnaltrexon hade inte 
högre grad av trombocythämning av tikagrelor två timmar efter att metylnaltrexon gavs jämfört med de 39 
patienter som lottades till placebo. Läkemedelskoncentrationen av tikagrelor skiljde sig inte heller signifikant 
mellan grupperna. Med andra ord hade injektionen av metylnaltrexon ingen positiv effekt på läkemedelsupptaget 
av tikagrelor hos patienter med ST-höjningsinfarkt som erhållit morfin och framtida studier bör söka efter andra 
alternativ till att förbättra läkemedelsupptaget hos denna patientkategori. 
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1 INTRODUCTION AND BACKGROUND 
1.1 PLATELETS IN PRIMARY HEMOSTASIS 
Platelet inhibition is a corner stone in the treatment of acute coronary syndrome (ACS) as 
platelet activation and aggregation are pivotal in the generation of arterial thrombosis. In case 
of atherosclerotic plaque rupture, a very prothrombotic surface is exposed to blood.  The 
traditional model of thrombus formation begins with platelet interaction with subendothelial 
tissue and prothrombotic factors like von Willebrand factor (vWF), fibronectin, collagen, and 
tissue factor. This interaction causes platelet activation and adherence to the damaged vessel, 
i.e. initiation of primary haemostasis. Normally, the healthy endothelium prevents this by 
expressing antithrombotic compounds such as prostacyclin-I2 and nitric oxide (1). After 
adhesion, the process of platelet activation is further amplified by production and release of 
several soluble platelet agonist, most importantly thromboxane A2 (TxA2) and adenosine 
diphosphate (ADP). TxA2 promotes platelet activation and is produced by cyclo-oxygenase 
(COX) from arachidonic acid, a process targeted by aspirin and other non-steroid anti-
inflammatory drugs (2). ADP is released from dense platelet granules and is very important in 
the process of thrombus formation as it interacts with P2Y-receptors on other circulating 
platelet, inducing a cascade reaction of platelet activation and aggregation. There are two key 
receptors in this group: P2Y1 and P2Y12 (3). The ADP-induced aggregation can be 
stimulated by both receptors, but is in fact dependent on their simultaneous activation (4). 
Activation of the G-protein coupled P2Y1-receptor leads to an initial phase of platelet 
activation by causing a change of the platelet shape and a weak platelet aggregation. This 
initial phase is followed by ADP interaction with the P2Y12-receptor (target for clopidogrel, 
ticagrelor, prasugrel, and cangrelor), which is more important for the growth and stabilization 
of the platelet aggregate. The ADP-P2Y12 binding activates the receptor coupled G-protein 
causing a complex intracellular signaling cascade (4), including inhibited phosphorylation of 
vasodilator-stimulated phosphoprotein (VASP) (5).  This results in an activation of fibrinogen 
receptor GP IIb/IIIa (also named integrin αIIbβ3), promoting enhanced platelet degranulation, 
release of more ADP, and stimulation of TxA2 production (7). The GP IIb/IIIa receptor 
enables platelet aggregation via the cross-linking process where platelets adhere to each other 
using the soluble adhesive protein fibrinogen to build up the aggregate. This receptor is also 
used as a pharmacological target with GPIIb/IIIa inhibitors (6).  Even though ADP and TxA2 
interact with different receptors, platelet activation through these agonists ultimately results in 
a platelet shape change, degranulation, and activation of fibrinogen receptors.  
Another very important soluble platelet agonist is thrombin, generated at the site of 
endothelial injury. It induces platelet aggregation via activation of it specific protease-
activated receptors (PAR), which is another pharmacological target (6). There is also a role of 
platelets in inflammation and atherosclerosis formation, partly through the expression of P-
selectin from activated platelets (7). Measurements of P-selectin can be used to assess platelet 
function after agonist stimulation ex vivo (8). 
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The above described model reflects the core elements of the initiation of thrombus formation, 
where the stabilization of the initial platelet aggregate is dependent on soluble agonists, 
especially ADP (9). This model is, however, a simplification as platelet aggregation has 
proven to be a more dynamic process than initially thought. In stenosed arteries the lumen is 
reduced and passing blood is exposed to high shear rates, i.e. shear stress. The mechanism of 
platelet aggregation has been shown to differ according to the level of shear stress, where 
there appears to be a mechanism of biomechanical platelet activation. Under these conditions, 
the soluble platelet agonists including TxA2, thrombin, and ADP probably play a “later” role 
in stabilization of the initial aggregated platelets (2). Moreover, in recent years new platelet 
receptors have been discovered, including several immunoreceptor tyrosine-based inhibition 
motif (ITIM)-containing receptors, which regulate signal transduction in platelets. The exact 
impact on platelet activation and aggregation of these receptors is not fully understood (10). 
To provide a more thorough explanation of the recent discoveries of platelet activation is, 
however, not the scope of this thesis. 
The secondary hemostasis, which secures and strengthens the platelet plug through the 
cleaving of fibrinogen to fibrin, is not described in this introduction. 
1.2 DUAL ANTIPLATELET TREATMENT  
In patients with acute coronary syndrome (ACS) and patients undergoing percutaneous 
coronary intervention (PCI), proper antiplatelet therapy is a cornerstone to reduce morbidity 
and mortality. Dual antiplatelet therapy (DAPT) with a combination of aspirin and an oral 
platelet P2Y12-inhibitor has been established in clinical use for almost 20 years (11). DAPT 
is with over 35 randomized large clinical trials including more than 225,000 patients, one of 
the most investigated treatment strategies in cardiovascular medicine (11).  
Aspirin, or acetylsalicylic acid, irreversibly inhibits and inactivates the two COX-enzymes 
(COX-1, and COX-2) in platelets and endothelial cells.  In platelets the inhibition of COX-1 
disables the creation of TxA2. A low dose aspirin treatment regime primarily inhibits the 
COX-1 dependent platelet activation via TxA2, while it has little effect on the COX-2 
function in e.g. endothelial cells. This inhibition of platelet COX-1 lowers the risk of 
atherothrombotic events and forms the cornerstone in the treatment of patients with 
established cardiovascular disease (12). 
Clopidogrel is an oral intestinally absorbed thienopyridine prodrug with little to no effect on 
ADP-induced platelet activation in its inactive form. When orally administrated, 85% of the 
absorbed clopidogrel is hydrolyzed by esterases to an inactive metabolite (13). The remaining 
15 % is in a two-step reaction, mediated by the hepatic cytochrome P-450 system, converted 
to the active but highly unstable metabolite R-130964. There are several hepatic CYP450 
enzymes involved in this process, most notably CYP2C19, which affects both steps of the 
metabolic reaction that generates R-120964. When exposed to platelets, this active metabolite 
forms an irreversible binding to the platelet’s P2Y12 receptors, inhibiting ADP-induced 
platelet aggregation (14). 
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In 2001, the landmark clopidogrel in unstable angina to prevent recurrent events (CURE) trial 
showed that DAPT consisting of clopidogrel in addition to aspirin reduced the composite 
endpoint of myocardial infarction, stroke or cardiovascular death (15). The subsequent PCI-
CURE study, which examined the subgroup of patients in the CURE trial who underwent 
PCI, showed that this treatment regime reduced the risk of cardiovascular death, myocardial 
infarction, or urgent target-vessel revascularization within 30 days with about a third 
compared with aspirin alone (16).  Treatment with clopidogrel was shown safer with fewer 
side effects than the previously introduced P2Y12-inbitor ticlopidine and thus replaced it in 
clinical practice (11).  
The antiplatelet response to clopidogrel is, however, very heterogeneous between patients. 
Many patients get a suboptimal platelet inhibition, i.e. a high on-treatment platelet reactivity 
(HPR), which is a strong risk factor for cardiovascular death, myocardial infarction, and stent 
thrombosis after PCI (17). In one meta-analysis of 25 studies with 3688 patients, the mean 
prevalence of HPR was 21% (95% CI 17-25%), but with a significant heterogeneity between 
studies. Despite different prevalence, HPR was associated with an increased risk for adverse 
cardiovascular events in most of the included studies (18). The response variability to 
clopidogrel treatment depends mainly on the generated amount of active metabolite, which 
may be due to clinical factors like non-compliance, or drug-drug interference with for 
example proton pump inhibitors. Other factors include impaired intestinal absorption or 
changed platelet function caused by diabetes, increased BMI, or ongoing acute coronary 
syndrome. Moreover, genetically caused loss-of-function in the CYP2C19 enzyme is known 
to cause HPR (19). 
1.3 NEWER MORE EFFICIENT P2Y12 INHIBITORS 
Due to the problems with heterogeneous antiplatelet response on clopidogrel, newer and 
more efficient platelet inhibiting drugs are now in clinical use in the setting of acute coronary 
syndrome, including the more potent P2Y12-receptor antagonists ticagrelor, prasugrel, and 
cangrelor, whereby the latter is a short-acting intravenous drug (6). Ticagrelor reversibly 
binds to platelets thereby inhibiting ADP-mediated platelet activation and aggregation. It 
does not need metabolic changes for its inhibitory effect but has active metabolites, most 
importantly AR-C124910XX (20). An oral loading dose (LD) of 180 mg ticagrelor results in 
a high degree of platelet P2Y12 inhibition (80-90%), normally within around two hours (21-
23). This is both a stronger and more rapid platelet inhibiting effect compared with 
clopidogrel, making ticagrelor a more attractive alternative in the situation of ACS, where a 
rapid onset of platelet inhibition is beneficial. The landmark study of Platelet Inhibition and 
Patient Outcomes (PLATO) showed benefits of DAPT using aspirin and ticagrelor over 
aspirin and clopidogrel in most subgroups of ACS patients. This is why today ticagrelor is 
routinely given to patients with ACS before coronary angiography, in the absence of 
contraindications (24).  
The potent P2Y12 inhibitors prasugrel and cangrelor have also been shown to reduce 
ischemic events compared with clopidogrel in ACS patients (25, 26), but as these P2Y12 
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inhibitors are not the main focus of this thesis the interested reader can find background 
reading on this elsewhere (6, 11).  
1.4 INCREASED BLEEDING RISK 
In contrast to patients on P2Y12-inhibitors who have HPR, those with a high grade of platelet 
inhibition are at risk for bleeding, which is associated with increased morbidity, mortality, 
and high costs (27, 28). The introduction of newer more potent platelet inhibitors has a trade-
off between decreased thrombotic complications and increased bleeding risk, which is an 
important consideration in for example the decision of treatment duration (11). 
Contrary to ischemic events such as cardiac death, myocardial infarction, or stent thrombosis, 
which all have clear definitions, bleeding definitions are very heterogeneous (28). Many 
bleeding definitions have been suggested over the years and the perhaps most commonly 
used is the Thrombolysis in Myocardial Infarction (TIMI) bleeding criteria, which were 
established in the 1980s (29). The original version of the TIMI bleeding has been adapted to 
better fit certain specific scenarios, such as surgery with coronary artery bypass grafting 
where bleeding is very common (28). Also, many other bleeding definitions have been 
established and used in varying frequency, which has increased variance in the incidence of 
bleeding events between studies. In an attempt to standardize bleeding definitions used in 
cardiovascular studies, the Bleeding Academic Research Consortium (BARC) published a 
consensus report including a bleeding definition to be used in future clinical trials (28). 
BARC standardized endpoint definitions were considered “…an important way to improve 
the quality and efficiency of clinical trials…” according to the corresponding editorial in 
Circulation (30). These definitions are nevertheless in need of further data-driven validation 
as they were based on consensus (30, 31). Also, the European Society of Cardiology Working 
Group on Thrombosis suggested that bleeding events in acute coronary syndromes and 
percutaneous coronary interventions should “be reported using more than one bleeding scale, 
one of which should be the BARC bleeding definition” (31). For this reason, Study II, which 
focused on bleeding events, included the BARC bleeding definition. It also includes the 
bleeding definition from the previously published Antiplatelet Therapy for Reduction of 
Myocardial Damage During Angioplasty-Bleeding (ARMYDA-BLEEDS) study, where 
patients in the lowest quartile of platelet aggregation according to platelet function testing had 
a significantly higher incidence of bleeding complications compared with the highest quartile 
of platelet aggregation (32). 
1.5 EVALUATION OF PLATELET P2Y12 INHIBITION 
Although patients with HPR are at greater risk for adverse cardiovascular events, it is not 
recommended to routinely screen for HPR among the patients receiving P2Y12-inhibiting 
drugs prior to angiography and PCI. The reason for this is simple. Even though on-treatment 
platelet reactivity has been shown an independent and reliable risk predictor of cardiovascular 
events, a benefit of individualized antiplatelet therapy on the basis of platelet function testing 
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has not been successfully proven (33). Moreover, standardization of the definitions of HPR 
has been an issue, as it depends on the type of testing equipment used. 
Many platelet function tests are available for evaluation of platelet inhibition and for the 
detection of HPR. The Plateletworks® assay, which relies on single platelet counting with a 
conventional cell counter before and after agonist stimulation in vitro, has shown predictive 
value for adverse thrombotic/ischemic events after PCI (34). This test has, compared with 
other available more common platelet function tests, such as Multiplate®, VerifyNow®, 
VASP-P assay®, and light transmittance aggregometry (LTA), not been validated in 
sufficiently large study samples (35). In Study I and II, this platelet function was used to 
evaluate P2Y12 platelet inhibition. The results of this assay are available within minutes, but 
a major disadvantage is that the platelet function testing needs to be conducted within 10 
minutes after blood sampling (34).  
Multiplate® rely on multiple electrode aggregometry (MEA), where an impedance 
aggregometer measure electrical impedance between two electrodes immersed in whole 
blood with hirudin anticoagulation. Stirring of the blood is performed in a semi-automatic 
fashion and after the addition of an agonist such as ADP, platelet aggregation inhibition of 
the agonist-specific receptor is measured. The results are available within a few minutes, and 
the results of the assay have been shown to have predictive value for both thrombotic and 
bleeding events in patients on P2Y12-inhibitors (36). Testing with MEA was conducted to 
evaluate platelet inhibition with ticagrelor in Study III. A disadvantage with MEA is that 
other platelet inhibiting drugs, such as GP IIb/IIIa inhibitors affect the results, i.e. it is not 
entirely P2Y12-specific. Moreover, the method requires some laboratory experience to 
conduct. 
Another method to assess platelet P2Y12-receptor inhibition is measurement of VASP 
phosphorylation, which is very specific for the P2Y12 receptor inhibition. As mentioned 
above, VASP is a second messenger in the P2Y12-receptor signaling and the ratio of 
phosphorylated and dephosphorylated VASP directly and selectively measures platelet 
P2Y12 inhibition. This is a major advantage, as other platelet inhibiting drugs such as GP 
IIb/IIIa inhibitors does not affect the testing results. A disadvantage with the VASP assay is 
that specialized laboratory equipment and staff experienced with flow cytometric analyses are 
needed (36). In Study IV, a novel version of the VASP assay relying on enzyme-linked 
immunosorbent assay (ELISA) was used, as it does not require a flow cytometer for the 
analysis and significantly lowered the analysis time requirements. Moreover, it enabled 
freezing of blood samples after initial activation and lysis before later centralized analysis, as 
previously described (37). 
1.6 IMPAIRED ONSET OF PLATELET P2Y12-INHIBITION IN ACS 
A steady state of platelet inhibition is normally achieved at around 6 hours after a LD of 
clopidogrel (38, 39).  However, in patients with ST-segment myocardial infarction (STEMI), 
the bioavailability of clopidogrel has been shown to be significantly decreased compared with 
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healthy controls (40). This may be due to a stress-related decrease in gastrointestinal motility 
including decreased gastric emptying and decreased small intestinal transit (41), which could 
explain the lower bioavailability of clopidogrel as drug absorption rate in the gastro-intestinal 
tract is largely determined by gastric emptying(42). However, opioids such as morphine, 
which is often administered to relief severe pain in STEMI patients, have also been reported 
to delay gastric emptying (43). This negatively impacts the uptake of clopidogrel, which was 
shown in a small randomized study of healthy volunteers, where morphine use significantly 
decreased the clopidogrel uptake and antiplatelet action (44). As the newer P2Y12 inhibitor 
ticagrelor has a peak concentration at around 2 hours after a LD of 180 mg ticagrelor, its use 
could perhaps counter the problem of belated uptake and effect in STEMI. The data on the 
uptake of ticagrelor originate mainly from healthy volunteers and patients with stable 
coronary artery disease (45-47). In ACS patients, however, the uptake has shown to be more 
unpredictable, especially in patients with ST-segment elevation myocardial infarction 
(STEMI) (48, 49). 
Among ACS patients in Sweden, non-ST elevation myocardial infarction (NSTEMI) 
represented the most common group during 2014 (50). In Sweden, these patients are usually 
given a LD of 180 mg ticagrelor upon diagnosis, according to European Society of 
Cardiology guidelines (51). When the planning for Study III was conducted, the 
pharmacokinetic properties of ticagrelor in the acute phase had not been thoroughly studied in 
ACS patients with NSTEMI. A small previous study evaluated several different ticagrelor 
loading and maintenance doses and a LD of 180 mg ticagrelor to P2Y12-naïve patients (n=7) 
resulted in a mean time to maximal ticagrelor concentration (Tmax) of 3 hours (52). Except for 
that study, the pharmacokinetics of a 180 mg LD of ticagrelor had not been evaluated in 
patients with NSTEMI. The idea behind Study III was that patients with NSTEMI, like those 
with STEMI might have a delayed onset of platelet inhibition, possibly due to an increased 
stress response and impaired gastrointestinal peristalsis.   
A LD of ticagrelor is currently recommended on top of aspirin as anti-platelet therapy in 
patients with ST-segment elevation myocardial infarction (STEMI) (11, 24).  However, a 
delayed onset of action, i.e. high prevalence of early HPR within the first hours have also 
been demonstrated in STEMI patients after orally administered ticagrelor (48, 49). In the 
“Administration of Ticagrelor in the Cath Lab or in the Ambulance for New ST Elevation 
Myocardial Infarction to Open the Coronary Artery” (ATLANTIC) study, pre-hospital 
ticagrelor administration did not improve pre-PCI coronary reperfusion, but stent-thrombosis 
was significantly lower at 30 days, when compared with in-hospital ticagrelor (53).  This is 
an indication that improvement of ticagrelor action with an earlier LD resulting in earlier 
antiplatelet effect is of benefit in STEMI patients. Today, most STEMI patients in Stockholm 
receive a 180 mg ticagrelor LD in addition to aspirin in the prehospital setting.  An early 
onset of ticagrelor effect in STEMI patients is considered important as an adequate platelet 
inhibition improves clinical outcome. 
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Morphine has also emerged as a predictor of belated antiplatelet effect after intake of the 
newer P2Y12 inhibitors prasugrel or ticagrelor (48). In a sub-study of the ATLANTIC study, 
use of morphine in patients with STEMI was shown to delay the onset of platelet inhibition 
after a 180 mg ticagrelor LD (37). These authors hypothesized that this interaction may have 
had an impact on the negative primary outcome of the ATLANTIC study, as there was an 
observed interaction between morphine treatment and ST-segment elevation resolution (53). 
In another recent trial, patients with acute myocardial infarction (64% STEMI) randomized to 
administration of morphine had a delayed uptake and antiplatelet response to ticagrelor, when 
compared with placebo (54).  
The morphine-induced delay in gastric emptying can be reduced with the opioid antagonist 
naloxone, which has been verified in morphine-treated women during labor (55). However, a 
drawback with naloxone is that it passes the blood-brain barrier (BBB), and thus attenuates 
the pain-reducing morphine effect.  Conversely, the opioid antagonist methylnaltrexone does 
not affect the morphine-mediated central analgesic effects due to a very limited passage over 
the BBB, and thus primarily acts as a peripheral morphine antagonist (56). The possible 
effect of this drug on the uptake of ticagrelor was evaluated in Study IV. 
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2 AIMS 
The specific aims were: 
♦ To investigate the ability of the Plateletworks® assay to identify patients pretreated 
with clopidogrel at increased risk for adverse clinical events after coronary 
angiography with or without PCI. 
 
♦ To investigate the relation between on-treatment platelet reactivity assessed with the 
Plateletworks® assay and the 30-day incidence of bleeding complications, as defined 
by the BARC and ARMYDA- BLEEDS definitions, after coronary angiography with 
and without PCI.                                                    . 
 
♦ To evaluate the ticagrelor uptake and platelet P2Y12 inhibition in patients with 
NSTEMI not receiving opioids and compare these data with those of patients with 
SCAD. 
 
♦ To evaluate if the peripheral opioid antagonist methylnaltrexone could improve 
platelet inhibition after a LD of 180 mg ticagrelor in morphine treated patients with 
STEMI. 
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3 METHODS 
3.1 STUDY DESIGN AND PATIENT SELECTION  
Study I and II were observational, prospective, single center studies based on the same 
cohort of 491 adult patients with ACS and patients with established coronary artery disease. 
All patients were on treatment with aspirin and clopidogrel before undergoing acute or 
elective coronary angiography with or without PCI between October 2006 and May 2011 at 
the Karolinska University Hospital in Solna, Sweden. Study I included the whole cohort, 
while in Study II 16 patients were excluded due to GP IIb/IIIa inhibitor use prior to the 
platelet function test or prasugrel use resulting in a cohort of 474 patients.  
Study III (NCT02292277), was a prospective, open-label, observational, single-center, phase 
IV pharmacokinetic and pharmacodynamic study performed at Södersjukhuset between 
October 2014 and October 2015, and the. Patients eligible for the study were P2Y12-inhibitor 
naïve patients with NSTEMI presenting at the emergency room. Inclusion criteria were as 
follows: 1) Diagnosis of NSTEMI (i.e., relevant symptoms associated with ischemic ECG 
changes (not categorized as STEMI) and/or relevantly increased cardiac markers). 2) An 
indication for a 180-mg ticagrelor LD. Exclusion criteria for the NSTEMI group were: 1) 
Ticagrelor contraindication; 2) Age <18 years; 3) Administration of any P2Y12 inhibitor 
during the week before inclusion; 4) Treatment with glycoprotein IIb/IIIa antagonists within 
48 hours before inclusion; 5) Ongoing morphine treatment. The control group of Study III 
consisted of P2Y12-inhibitor naïve patients with SCAD, who underwent elective diagnostic 
coronary angiography at the cardiac catheterization laboratory at Södersjukhuset. Inclusion 
criteria for the SCAD control group were as follows: 1) Documented stable coronary artery 
disease; 2) Administration of a 180-mg ticagrelor LD. Exclusion criteria for the control group 
were: 1) Ticagrelor contraindication; 2) ACS within the last 3 months; 3) Age <18 years; 4) 
Administration of any P2Y12 inhibitor during the week before inclusion; 5) Treatment with 
glycoprotein IIb/IIIa antagonists within 48 hours before inclusion; 6) Ongoing morphine 
treatment.  
Study IV (EU-no. 2015-002910-65 and NCT02942550) was a prospective, single-blinded, 
randomized, placebo-controlled, multicenter trial performed at Södersjukhuset and 
Karolinska University Hospital Huddinge in Stockholm, Sweden. Patient inclusion was 
performed between November 2016 and December 2017. Patients considered for inclusion in 
the study were P2Y12-inhibitor naïve patients with STEMI presenting at the cardiac 
catheterization laboratory. Inclusion criteria were: 1) Diagnosis of STEMI including presence 
of typical symptoms, e.g. chest pain for more than 15 minutes together with new ST-segment 
elevation (>1mm (0.1mV) in at least two contiguous leads in the absence of left branch 
bundle block (LBBB) or signs or left ventricular hypertrophy on a 12-lead ECG; 2) Intake of 
a 180 mg oral LD of ticagrelor given before initiation of coronary angiography; 3) Analgesic 
treatment with intravenous morphine administered before initiation of coronary angiography. 
Exclusion criteria were: 1) Cardiac arrest; 2) Body weight >114 kg; 3) Vomiting after 
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ticagrelor intake; 4) Treatment with naloxone before inclusion or during the sampling period; 
5) Inability to understand study outline and instructions; 6) Any methylnaltrexone bromide 
contraindication, including known hypersensitivity to the active substance or to any of the 
excipients and/or known or suspected mechanical gastro-intestinal obstruction or other acute 
surgical abdominal conditions; 7) Age <18 years; 8) Women in fertile age; 9) Administration 
of ticagrelor, clopidogrel, or prasugrel within 7 days before onset of STEMI symptoms; 10) 
Treatment with cangrelor; 11) Ongoing long-term opioid treatment. 
3.2 CLINICAL INTERVENTIONS AND PROCEDURES 
In Study I and II, all patients not previously on clopidogrel and/or aspirin treatment received 
a LD of clopidogrel (150 to 800 mg) in addition to aspirin (300 to 500-mg LD, followed by 
75 mg/day) before coronary angiography. If PCI was performed, a daily maintenance dose of 
clopidogrel 75 mg was post-procedurally recommended in addition to aspirin for one year in 
patients receiving drug-eluting stents, whereas 3 months of dual antiplatelet treatment was 
recommended to patients receiving bare-metal stents. Patients already receiving clopidogrel 
treatment for >5 days before coronary angiography did not receive additional LD, but 
continued with their daily maintenance dose (75 mg once daily). Ten patients were receiving 
warfarin treatment, which was discontinued ≥7 days before coronary angiography. All 
interventions were performed according to international guidelines (57, 58). The femoral 
approach was used in all but 32 interventions, in which the radial approach was used, and 
unfractionated heparin was given in weight-adjusted doses (50 to 100 IE/kg). The sheath size 
was 6 Fr. A vascular closure device (Angio-Seal®; St. Jude Medical, St. Paul, Minnesota) was 
used in 247 patients. A compression assist device (Femostop®; St. Jude Medical) was used in 
the rest of the cohort and in patients with vascular closure devices when required for 
hemostasis. Use of periprocedural antiplatelet agents other than clopidogrel and aspirin, for 
example, glycoprotein IIb/IIIa inhibitors, was at the discretion of the interventionists. 
In Study III, NSTEMI patients were included in the study upon arrival to the emergency 
room before receiving a 180-mg LD of integral ticagrelor pills immediately after NSTEMI 
diagnosis, as prescribed by the responsible physician. For the control group, the responsible 
physician decided to administer a LD of 180 mg ticagrelor after examining the coronary 
anatomy and before initiation of PCI. 
Study IV included P2Y12-inhibitor naïve patients with STEMI presenting at the respective 
cardiac catheterization laboratory. All interventions and additional medication were 
performed at the discretion of the interventional cardiologists. 
3.3 STUDY INTERVENTIONS 
In Study I and II, a 4-ml blood sample was drawn from the arterial line at the start of each 
coronary angiography procedure for assessment of platelet function. A research nurse, who 
was well familiar with the testing equipment and had received training from the 
manufacturer, conducted all blood sampling and subsequent platelet function testing. The 
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physicians responsible for the patients during their hospital stays were not aware of the 
platelet function test results. Written informed consent was obtained from all patients.  
In Study III, samples of venous blood were collected for pharmacokinetic assessment into 
lithium heparin tubes and placed on ice at the time-points shown in TABLE 1. The blood 
samples were then centrifuged at 1500 g at 4ºC for 10 min within 30 min of blood sampling. 
The resulting plasma samples were within 30 min of centrifugation stored at the 
Södersjukhuset’s biobank below −20ºC until analyzed. Samples of venous blood were taken 
into hirudin tubes for pharmacodynamic evaluation, at the time-points shown in TABLE 1. The 
first 3–5mL of blood was discarded to avoid spontaneous platelet activation. 
 
In Study IV, oral consent was given upon arrival to the cardiac catheterization laboratory. 
Patients who fulfilled all the inclusion criteria and no exclusion criteria were randomized to 
either active treatment with methylnaltrexone or placebo, as specified below. All patients 
were asked to leave a written informed consent after completion of PCI. Randomization was 
performed thorough pre-sealed envelopes in a 1:1 fashion in blocks of four patients. To 
facilitate reproducibility, randomization was performed with the tool available at 
www.randomization.com, which enables simple block randomization using equal fixed block 
sizes. Stratification was performed for the two participating centers and also for inferior 
versus anterior or lateral STEMI. 
In Study IV, blood samples were taken for pharmacodynamics and pharmacokinetic 
evaluation. This was done at the start of the coronary angiography from the arterial line to 
avoid possible sampling failure that could conceivably delay the PCI.  The responsible 
personnel in the cardiac catheterization laboratory administered the study drug 
methylnaltrexone (Relistor®) or placebo after initial blood sampling. Methylnaltrexone was 
given as a single intravenous injection of 8 mg (0.4 ml solution) to patients weighing 38–61 
kg or 12 mg (0.6 ml solution) to patients weighing 62–114 kg. The placebo treatment of 0.9% 
sodium chloride was given as a single intravenous injection of 0.4 or 0.6 ml according to the 
same weight schedule as the study drug. The study drug or placebo was administered using 
an unlabeled injection syringe, thus blinding patients to their respective treatment. Patients 
were asked to state self-estimated pain using a visual analogue scale (VAS) at baseline, at 
one, and two hours. 
TABLE 1. Blood sampling for  pharmacokinetic and pharmacodynamic assessment in Study III 
 Time (h) relative to ticagrelor  LD 
Pre-dose 1 2 3 4 5 6 
Ticagrelor pharmacokinetic sampling x x x x x x x 
ADP-induced platelet aggregation x x x x x x x 
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3.3.1 Assessment of platelet inhibition 
In Study I and II, assessment of ADP-induced platelet aggregation was performed with the 
Plateletworks® assay (Helena laboratories, Beaumont, Texas). The test was performed <10 
minutes after blood sampling. The baseline platelet count was obtained by the addition of 1 
ml whole blood to the first tube, primed with the synthetic anticoagulant 
ethylenediaminetetraacetic acid (EDTA). One milliliter of whole blood was then added to the 
second tube, containing citrate and adenosine diphosphate (20 µmol), inducing platelet 
aggregation (FIGURE 1). For each tube, the platelet count was then measured with a cell 
counter (ABX Micros 60; Horiba ABX Diagnostics, Holliston, Massachusetts). Because 
platelet aggregates exceed normal platelet size, it is possible for the cell counter to 
discriminate between aggregated and non-aggregated platelets on the basis of size. The 
difference in platelet count between the two samples was used as a measurement of platelet 
aggregation. 
 
 
 
 
 
FIGURE 1. Agonist-induced platelet aggregation with examples of platelet count (reprinted 
with permission from Helena laboratories, Beaumont, Texas) 
For Study III, analysis of ADP-induced platelet aggregation in whole blood was performed 
with multiple electrode aggregometry (MEA) using 6.5 µmol ADP as agonist within 2 hours 
of blood sampling. All materials used were obtained from the manufacturer (Roche 
Diagnostics International Ltd, Rotkreuz, Switzerland). High on-treatment platelet reactivity 
(HPR) was defined as > 46 ADP-induced aggregation units (AU) (59). 
In Study IV, an initial baseline blood sample was taken from the arterial line and further 
blood sampling was performed at one and two hours after the patients received either 
methylnaltrexone or placebo. Samples of venous blood were taken into 0.109 M trisodium 
citrate tubes for pharmacodynamic evaluation. Blood samples were stored at room 
temperature and within 48 hours activated and lysed by the participating research nurses 
according to the manufacturer’s instructions. The blood samples were then immediately 
frozen and stored below -20°C until analysis, as previously described (37). Analysis of 
P2Y12 inhibition blinded for study drug/placebo was performed centrally at Södersjukhuset 
by determination of platelet reactivity index (PRI) with an ELISA-based assay for the 
measurement of phosphorylated vasodilator-associated stimulated phosphoprotein (VASP) 
(CY-QUANT VASP/P2Y12, BioCytex, Marseilles, France).  
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3.3.2 Measurements of drug concentrations 
In Study III, plasma concentrations of ticagrelor and its active metabolite AR-C124910XX 
were determined by validated methods (high-performance liquid chromatography and tandem 
mass spectrometry detection; LC-MS/MS) at a certified laboratory (Covance Central 
Laboratories, Indianapolis, Indiana, USA). The lower limits of detection were 2.50 ng/mL for 
both ticagrelor and AR-C124910XX.  
For pharmacokinetic assessment in Study IV, blood samples were collected into lithium-
heparin tubes and then cooled prior to centrifugation at 1500 g for 10 min at 4ºC. The 
resulting plasma samples were then stored at the Södersjukhuset’s biobank below −20ºC until 
analyzed. Plasma concentrations of ticagrelor and its active metabolite, AR-C124910XX, 
were determined by a liquid chromatography – high resolution mass spectrometry method 
(LC-HRMS) and followed an earlier published procedure (60). Plasma concentrations of 
morphine were analyzed using the same methods. The used instrument was an UHPLC-Q 
Exactive high-resolution mass spectrometer (Thermo Scientific, Waltham, MA, USA) 
equipped with a Dionex 3000 UltiMate LC system consisting of an ultra-high pressure dual 
pump, an auto-sampler, solvent degasser, and a thermostated column oven. The TraceFinder 
software v4.2 was used for instrument control and data evaluation.  
After thawing, 0.1 mL of plasma was added into a 7 mL glass test tube. Thereafter, 0.2 mL of 
acetonitrile containing internal standards (10 ng ticagrelor-d7, 10 ng ticagrelor metabolite-d7, 
8 ng morphine-d3) was added during vortexing. The prepared sample was centrifuged at 
3400g for 5 minutes and 150 µL was transferred into a new glass-test tube. After evaporation 
to dryness in a vacuum centrifuge the residue was re-dissolved in 60 µL of 50% acetonitrile 
(10% for morphine) and transferred into an auto-sampler vial. 
A volume of 1 µL was injected into the LC-HRMS system. Chromatographic separation was 
achieved using a Hypersil C18 column (particle size 1.9 µm, 2.1 mm x 100 mm, Thermo 
Scientific) operating at a column temperature of 40°C, and using gradient elution with a 
buffer A (0.1 % formic acid in water) and a buffer B (0.1% formic acid in acetonitrile) with a 
flow rate of 0.5 mL/min. The MS was operated in full scan positive electrospray ionization 
mode at 70,000 resolution setting. Extracted ion chromatograms with 10 ppm tolerance were 
used for peak area measurements. The exact masses of the protonated molecules were m/z 
523.1934 for ticagrelor and 530.2373 for the d7 analogue, m/z 479.1671 for ticagrelor 
metabolite and 486.2111 for the d7 analogue, m/z 286.1438 for morphine and 289.1626 for 
the d3 analogue. 
Calibration curves using fortified plasma standards were using the following concentrations: 
5, 30, 100, 200, 600, 1200, 2000 ng/mL for ticagrelor and ticagrelor dealkylated metabolite 
(ALSAChim, Strasbourg, France), and 2, 12, 40, 80 ng/mL for morphine (Cerriliant Co, 
Round Rock, Texas, USA). Internal standards were from the same companies. The 
correlation coefficients (r) of the respective calibration curves generated during the validation 
was >0.999 for all three analytes. The results of the quality controls run together with the 
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study samples are described in TABLE 2. The lower limits of detection were 5.0 ng/mL for 
both ticagrelor and AR-C124910XX. 
TABLE 2. Drug concentration analysis quality control 
Analyte Assigned concentration, 
ng/mL 
Measured concentration, 
ng/mL 
Coefficient of 
variation (%) 
n 
Ticagrelor 15 17.0 5.5 10 
 180 195 5.1 10 
 1000 1131 4.6 10 
AR-C124910XX 15 14.0 6.4 10 
 180 188 1.9 10 
 1000 1069 1.6 10 
Morphine 6 5.6 2.5 10 
 72 69 2.2 10 
3.4 FOLLOW-UP AND END-POINTS 
The primary end-point in Study I was myocardial infarction (ischemic symptoms and a 
spontaneous increase in biochemical cardiac markers, i.e. not periprocedural or 
postprocedural infarction). Moreover, secondary end-points included definite stent 
thrombosis (confirmed via angiography), death, and a composite endpoint (nonfatal 
myocardial infarction, all-cause death, or definite stent thrombosis) as in the Do Platelet 
Function Assays Predict Clinical Outcomes in Clopidogrel-Pretreated Patients Undergoing 
Elective PCI (POPULAR) study (34). Other secondary end-points were rehospitalization due 
to cardiovascular causes, rehospitalization due to chest pain specifically, reangiography, and 
confirmed stenosis in another coronary vessel. Patients were followed for three months after 
coronary angiography. Clinical outcome data were collected from the electronic medical 
record system in Stockholm, which also is continuously and accurately updated regarding all 
deaths in Sweden via the electronic online Swedish Population Register. Further follow-up 
was done via the Swedish Web-system for Enhancement and Development of Evidence-
based care in Heart disease Evaluated According to Recommended Therapies 
(SWEDEHEART) registry, which continuously gathers information about patient’s clinical 
presentation, complications from interventions, and outcomes for all coronary procedures, 
including surgical interventions. The compliance of clopidogrel during the follow-up was 
monitored in all patients via follow-up phone calls. One person was responsible for collecting 
of follow-up data and was not aware of platelet function data. 
For Study II, data on in-hospital bleeding events were prospectively acquired, including 
location and extent, laboratory data, imaging data, medications, and treatment. The data on 
out of hospital bleeding events that did not require direct visits to health care professionals 
were registered at later routine follow-up visits. The study database and patients’ medical 
records were re-examined for every bleeding event by two researchers blinded to platelet 
aggregation to classify them according to the bleeding definitions. The primary outcome was 
the 30-day incidence of bleeding complications after coronary angiography in relation to 
quartile distribution of on-treatment platelet reactivity measured by Plateletworks®. Bleeding 
was defined according the criteria of BARC. In essence, this bleeding definition classifies 
bleeding events as: Type 0 (no bleeding); Type 1 (minor bleeding which does not require 
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treatment by a healthcare professional), type 2 (any overt actionable sign of hemorrhage that 
requires intervention, hospitalization, increased level of care, or prompting evaluation); Type 
3a (Overt bleeding causing a hemoglobin drop of 30 to <50 g/L, or require transfusion); Type 
3b (Overt bleeding causing: a hemoglobin drop of ≥50 g/L, cardiac tamponade, need for 
surgical intervention, need for vasoactive agents); Type 3c (intracranial hemorrhage, 
intraocular bleeding compromising vision); Type 4 (CABG-related intracranial bleeding 
within 48 hours, reoperation after sternum closure to control bleeding, ≥5 red packed blood 
cells transfused within 48h, ≥2L chest tube output within 24h); Type 5 (5a probable fatal and 
5b definite fatal bleeding) (28). Moreover, Study II included the bleeding definition used in 
the ARMYDA-BLEEDS study (>10-cm hematoma, pseudoaneurysm, arteriovenous fistula, 
or major Thrombolysis In Myocardial Infarction (TIMI) bleeding criterion: intracranial or 
associated with a decrease in hemoglobin ≥50 g/L or >15% drop in hematocrit) (32). The 
National Cardiovascular Data Registry (NCDR) Cath- PCI Registry model was used for 
retrospective evaluation of preprocedural risk for bleeding. This predictive risk score is based 
on the variables ST-segment elevation myocardial infarction, age, body mass index, previous 
PCI, chronic kidney disease, shock, cardiac arrest <24 hours, gender, hemoglobin level, and 
PCI status (61). After returning to a referring hospital, 1 patient died from momentary 
iatrogenic lung bleeding during a chest drainage procedure, which aimed to evacuate a 
pleural effusion. This bleeding event was not regarded as an outcome for this study, because 
according to the autopsy protocol, it was a direct result of a surgical trauma. 
In Study III, the primary endpoint was the time to maximum concentration (Tmax) of 
ticagrelor after a 180 mg LD. Secondary endpoints were Tmax of the active ticagrelor 
metabolite AR-C124910XX, evaluation of the relationship between plasma concentrations of 
ticagrelor and the pharmacodynamic response after a 180-mg ticagrelor LD, and frequency of 
HPR at 2 hours after a 180-mg ticagrelor LD. The safety endpoint was the occurrence of any 
serious adverse events during the sampling period. 
In Study IV, the primary endpoint was the prevalence of HPR, defined as PRI ≥50% 
determined by the VASP assay (62) two hours after randomization and subsequent 
intravenous injection of either study drug or placebo. Secondary endpoints were: 1) 
Differences in ticagrelor and AR-C124910XX concentrations at one and two hours after 
randomization; 2) Difference in PRI at one and two hours after randomization; 3) Difference 
in patients´ subjective pain according to VAS. 
3.5 ETHICS 
All studies were conducted in accordance with the Declaration of Helsinki. For Study I, II, 
and III, written informed consent was obtained from all patients prior to any study-related 
procedures. The regional human research ethics committee in Stockholm, Sweden, approved 
the studies (reference numbers Study I and II: 2006/272-31/2 and 2013/604-32, Study III: 
2014/1174-31/1 and 2014/2131-32). 
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In Study IV, an initial oral consent was given upon arrival to the cardiac catheterization 
laboratory. All patients were asked to leave a written informed consent after completion of 
PCI. Study IV was approved by the Swedish Medical Product Agency (EU-no. 2015-
002910-65) and the regional ethical review board in Stockholm (reference numbers 
2015/1911-31/4, 2016/838-32, 2016/1983-32, 2016/1824-32, and 2017/413-32). 
3.6 STATISTICS 
3.6.1 Sample size calculations 
The sample size calculation for Study I was primarily based on a similar study conducted by 
Matetzky et al., which included 70 patients with STEMI. Their study was based on testing 
with ADP-induced aggregometry to evaluate platelet reactivity, and 88% of the events 
occurred in the quartile with clopidogrel resistance (63). For Study I, with a more unselected 
patient population, a lower frequency of patients with STEMI was expected. Internal data 
from the Karolinska University Hospital had previously shown an incidence around 5% of 
adverse cardiovascular events within 12 months after PCI. In Study I, an assumption based 
on the study by Matetzky et al. was made that 80% of the events would be in the two 
quartiles with the highest platelet aggregation while on clopidogrel treatment (64). The power 
calculation showed that with 90% power it would require 424 patients to demonstrate a 
significant difference between the groups (P<0.05). 
For Study II, a sample size calculation was done on the basis of the ARMYDA-BLEEDS 
study, which showed 10.1% and 1.3% incidence rates of bleeding in the first and fourth 
platelet aggregation quartiles, respectively (32). For Study II, assuming that the bleeding 
event rate would be similar, it would require 85 patients in each platelet aggregation quartile 
(a total of 340 patients) to show a statistical difference between the first and the fourth 
quartiles (p <0.05, 80% power).  
For Study III, the median Tmax in the SCAD control group was before the study expected at 
approximately 2 hours after a 180 mg LD, with a range between 1 and 8 hours (47). A rough 
standard deviation estimate of 1.25 hours was obtained from this range using the formula !" (!"#!"#$)!!" (!"#  !"#$)!   from a statistical textbook by Dixon et al (65). A statistician 
estimated k to 9.5 from a natural distribution table. The estimated standard deviation of 0.22 
on the logarithm scale was then calculated using the calculation above. For the study group 
with NSTEMI, a larger standard deviation can be expected and was estimated with the 
following formula provided by the statistician: 0.22! × 2  = 0.31. To make a sample size 
calculation possible, the above calculated standard deviations were anti-logged using the 
exponential function and found to be 1.25 hours and 1.36 hours, respectively. For the power 
calculation, a 50% delay in median ticagrelor Tmax (1 hour delay) was considered, as this can 
be regarded as a clinical significant difference. A power calculation with the above described 
time to Tmax and estimated standard deviations, showed that a study with 80% power would 
require 40 patients in the study group and 20 patients in the control group. 
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For Study IV, The sample size calculation was based on results from a previous sub-study of 
the ATLANTIC trial (37), which showed that STEMI patients treated with morphine had a 
delayed onset of platelet inhibition after a 180 mg LD of ticagrelor. In patients treated with 
morphine, 14 out of 22 patients (64%) had a high on treatment platelet reactivity (HPR), 
defined as VASP-PRI ≥50%, 3 hours after study inclusion (around 2 hours after PCI). 
Among the STEMI patients who did not receive morphine 3 out of 15 patients (20%) had a 
HPR 3 hours after study inclusion. A sample size calculation showed that at least 25 patients 
would be needed in each group to obtain a significant difference between the groups (p<0.05, 
90% power). To allow for stratification according to inferior or lateral/anterior STEMI, we 
aimed to include 40 patients in each group.  
3.6.2 Statistical analyses 
In Study I-III, continuous variables were expressed as mean and SD for normally distributed 
continuous variables, and compared using the Student’s t-test, whereas non-normally 
distributed variables were expressed as median with interquartile range (IQR) and compared 
with the Mann-Whitney U-test/Wilcoxon rank-sum test. Categorical variables were in Study 
I-IV presented as no. (%) and compared using the χ2-test or the Fisher’s exact test. A two-
tailed P-value <0.05 was considered significant. In Study I and II, receiver operating 
characteristic (ROC) curve analysis was performed to establish a cutoff of platelet 
aggregation with the Plateletworks® assay for the prediction of the respective endpoints.  
Statistical analyses were performed using SPSS version 20.0 in Study I, version 21.0 in 
Study II, version 22.0 in Study III, and version 24.0 in Study IV (IBM Corp, Armonk, NY). 
Moreover, Stata statistical software: Release 14 (StataCorp LP, College Station, TX) was 
used in Study IV. 
In Study I, Spearman’s rank correlation was used to compare variables that were not 
normally distributed. Unadjusted odds ratio (OR) calculations for the primary and secondary 
end-points were performed. Survival analysis was performed via Kaplan–Meier curve, and 
differences between groups were analyzed with the log-rank test. To identify potential 
confounders and variables that correlated with HPR, a logistic regression analysis was 
performed. The variables included were age, sex, BMI, diabetes, smoking, LD or no LD, and 
co-medication (including proton pump inhibitors and statins).  
For Study II, Patients were divided into quartiles according to ADP-induced platelet 
aggregation. Normal distribution for continuous variables was tested with the Shapiro-Wilk 
test. To identify possible variables associated with bleeding, an initial univariate Cox 
regression analysis was performed. Variables with p values <0.10 in the univariate analysis 
were considered for the stepwise forward and backward manual multivariate Cox regression 
analysis. The bleeding events in the different quartiles over time were visualized with 
Kaplan-Meier curves.  
In Study III, Continuous variables were tested for normality using the Shapiro-Wilk test. For 
inference, the Student’s t-test was used for normally distributed variables and the Mann–
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Whitney U-test for non-normally distributed variables. Categorical variables were described 
as numbers with percentages and compared with either the χ2-test or Fisher’s exact test. 
Calculations of the area under the curves (AUC) were performed using the trapezoid rule for 
the ticagrelor and AR-C124910XX concentrations. A Spearman’s correlation analysis 
between the ticagrelor concentrations and the platelet aggregation was performed.  
In Study IV, a conservative approach was taken where all continuous variables were 
described using median and IQR and tested using non-parametric tests due to the relatively 
small sample size, and because many variables were non-normally distributed. 
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4 RESULTS 
4.1 STUDY I 
In total, 491 patients on aspirin and clopidogrel were included and clinical outcome was 
available for all patients except one (0.2%). ROC curve analysis assessed if platelet function 
testing could differentiate between patients with and without myocardial infarction (primary 
endpoint) within the 3 months follow-up (FIGURE 2). The area under the curve (AUC) was 
0.60 (95% CI 0.49–0.70) with a sensitivity of 66.7% and a specificity of 60.9%. The optimal 
cutoff was found to be 82.3% platelet aggregation. Patients were grouped into HPR and 
normal on-treatment platelet reactivity using this cutoff. 
Demographic characteristics are listed in TABLE 2. In total, 196 patients (39.9%) had HPR 
(≥82.3% on-treatment platelet aggregation). Patients with HPR group had significantly higher 
BMI (28.3±4.4 vs. 26.7±4.6, p<0.001). Moreover, PCI was more common in the HPR group 
(62.8 vs. 51.9%, p=0.02) and they received a clopidogrel LD more frequently (78.1 vs. 
67.1%, p=0.01). Analysis with logistic regression showed that independent predictors of HPR 
were age calculated for a 10-year increase (OR, 1.26; CI, 1.03–1.54; p=0.02), clopidogrel LD 
received (OR, 1.73; CI, 1.04–2.87; p=0.04), and BMI using a 10-unit increase (OR, 2.34; CI, 
1.43–3.82; p= 0.001).  
As depicted in TABLE 3, the primary end-point myocardial infarction within the three months 
follow-up was significantly more frequent in patients with HPR (5.1 vs. 1.7%; OR, 3.12; CI, 
1.05–9.27; p=0.03). Moreover, rehospitalization within three months for cardiovascular 
causes was significantly more common in patients with HPR (23.0 vs. 14.2%, OR 1.80, CI 
1.13–2.86, p=0.01, TABLE 3).  
The difference in the incidence of myocardial infarction is also illustrated in FIGURE 3. 
Myocardial infarction was more common in patients receiving a clopidogrel LD compared 
with those already on maintenance therapy at inclusion (14 of 351 vs. 1 of 140; p=0.06). Of 
the 276 patients who underwent PCI, 9 (3.3%) experienced a myocardial infarction within 3 
months, compared with 6 (2.8%) of the 215 patients who underwent coronary angiography 
without PCI (p= 0.76).   
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TABLE 2. Demographic characteristics including comparisons between patients with and without HPR 
     On-treatment platelet reactivity   
 
Characteristic 
 
Total cohort*   
(n=491) 
Normal, <82.3% 
aggregation* 
(n=295, 60.1%) 
High, ≥82.3% 
Aggregation* 
(n=196, 39.9%) 
 
 p value 
Clinical parameters   
    Age, years 65.0 ± 10.7 64.4 ± 10.1 66.0 ± 11.4 0.11 
 Male gender 382/491 (77.8) 226 (76.6) 156 (79.6) 0.44 
 BMI, kg/m2 27.3 ± 4.6 26.7 ± 4.6 28.3 ± 4.4 <0.001 
 Hypertension† 268/490 (54.7) 156 (53.1) 112 (57.1) 0.37 
 Diabetes mellitus 122/491 (24.8) 71 (24.1) 51 (26.0) 0.62 
 Current smoking 95/491 (19.3) 57 (19.3) 38 (19.4) 0.99 
 Family history‡ 208/481 (43.2) 123 (42.7) 85 (44.0) 0.77 
 Prior myocardial 
infarction 
146/490 (29.7) 87 (29.5) 59 (30.1) 0.89 
 Prior PCI 105/491 (21.4) 60 (20.3) 45 (23.0) 0.49 
 Prior CABG 71/490 (14.5) 46 (15.6) 22 (12.8) 0.37 
Medication   
 Aspirin  470/491 (95.7) 282 (95.6) 188 (95.9) 0.86 
 GP IIb/IIIa-inh. prior to 
Plateteletworks® testing 
16/491 (3.3) 12 (4.1) 4 (2.0) 0.22 
 Received clopidogrel LD 351/491 (71.5) 198 (67.1) 153 (78.1) 0.01 
 -800 mg 1/491 (0.2) 1 (0.3 0 (0.0) 1.0 
 -600 mg 98/491 (20.0) 56 (19.0) 42 (21.4) 0.51 
 -450 mg 5/491 (1.0) 3 (1.0) 2 (1.0) 1.0 
 -300 mg 244/491 (49.7) 137 (46.4) 107 (54.6) 0.08 
 -150 mg 3/491 (0.6) 1 (0.3) 2 (1.0) 0.57 
Time from LD to  
coronary angiography  
    
<6 hours 20/432 (4.6) 6 (2.4) 14 (7.7) <0.01 
6-24 hours 92/432 (21.3) 40 (15.9) 52 (28.7) 0.001 
Already on clopidogrel 
maintenance dose 
140/491 (28.5) 97 (32.9) 43 (21.9) 0.01 
 Lipid-lowering drug  417/491 (84.9) 244 (85.9) 173 (83.6) 0.47 
 Proton pump inhibitors 79/491 (16.1) 48 (16.9) 31 (15.0) 0.57 
Laboratory data    
 Platelet count, x109/L 220.8 ± 59.9 220.8 ± 59.9 219.9 ± 56.2 0.87 
Procedural characteristics    
 Acute coronary 
angiography 
352/491 (71.7) 213 (72.2) 139 (70.9) 0.76 
  PCI performed 276/491 (56.2) 153 (51.9) 123 (62.8) 0.02 
*Data are presented as mean ± SD for quantitative variables, and as no. (%) for qualitative variables. 
† Defined as documented and treated hypertension. 
‡ Defined as documented family history or stated by patients themselves. Regarded significant with first 
degree relatives <50 years with cardiovascular disease. 
Abbreviations: BMI, body mass index; CABG, coronary artery bypass graft surgery; HPR, high on-treatment 
platelet reactivity; PCI, percutaneous coronary intervention. 
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TABLE 3. Clinical outcome at 3 months post coronary angiography 
    On-treatment platelet reactivity   
 
Clinical event 
(≤ 3 months) 
Normal, <82.3% 
aggregation* 
(n=295, 60.1%) 
High, ≥82.3% 
Aggregation* 
(n=196, 39.9%) 
 
 OR (95% CI) 
 
p value 
Primary end-point 
 Myocardial infarction 5 (1.7 )  10 (5.1 ) 3.12 (1.05-9.27) 0.03 
Secondary end-points     
 Stent thrombosis 3 (1.0) 4 (2.0) 2.03 (0.45-9.16) 0.45 
 Death  5 (1.7) 7 (3.6) 2.15 (0.67-6.87) 0.24 
 Composite end-point† 11 (3.7 ) 14 (7.1) 1.99 (0.88-4.47) 0.09  
 Re-hospitalization‡ 42 (14.2) 45 (23.0) 1.80 (1.13-2.86) 0.01 
 Re-hospitalization due to 
chest pain 
30 (10.2) 33 (16.8) 1.79 (1.05-3.04) 0.03 
 Re-angiography 21 (7.1) 18 (9.2) 1.32 (0.68-2.55) 0.41 
 Stenosis in another vessel  
6 (2.0) 
 
8 (4.1) 
 
2.05 (0.70-6.00) 
 
0.18 
*Data are presented as No. (%). 
† Includes all-cause death, as well as non-fatal myocardial infarction and stent thrombosis.  
‡ Re-hospitalization due to cardiovascular causes. 
Abbreviations: OR, odds ratio; CI, confidence interval. 
FIGURE 2. Receiver operating characteristics (ROC) 
curve. ROC curve analysis showing correlation between 
platelet aggregation and myocardial infarction (primary 
endpoint). 
 
FIGURE 3. Kaplan-Meier curve  
The graph shows the cumulative incidence of 
myocardial infarction within three months. Patients 
with on-treatment platelet reactivity had a 
significantly higher incidence, log-rank: p=0.03. 
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4.2 STUDY II 
The patients (n=474) were divided into quartiles according to on-treatment platelet reactivity. 
Demographic data are shown in TABLE 4. The clopidogrel LDs were found evenly distributed 
between the different quartiles. The time from clopidogrel LD to coronary angiography was 
higher in quartile 1 compared with quartile 4.  
Procedural characteristics and clinical data are shown in TABLE 5. STEMI was significantly 
more common in the highest quartile of platelet aggregation compared with the lowest 
quartile. 
Data on bleeding events within 30 days were available in all patients but one (0.2%). Two 
patients had bladder or urethral bleeding complications, three had gastrointestinal bleedings, 
one had an intracranial bleeding, one had an eye bleeding, and the remaining bleeding 
complications were entry-site bleedings of different degree. The most extensive bleeding was 
included in the analysis if more than on bleeding event occurred within 30 days. 
The incidence of type ≥1 BARC bleeding was 26.8% (127 of 474 patients; TABLE 6). Patients 
who had type ≥1 BARC bleeding had a higher median NCDR CathPCI risk score compared 
with those without bleeding (70 [IQR 55 - 80] vs. 60 [IQR 50 - 75], p=0.019). Median 
platelet aggregation was lower in patients with type ≥1 BARC bleeding compared with those 
without bleeding (51.0% [IQR 32.8% - 84.0%] vs. 79.1% [IQR 52.5% - 92.0%], p= 0.001). 
As shown in TABLE 6, Patients in the lowest quartile of platelet aggregation had a higher 
incidence of ≥1 BARC bleeding compared with the fourth quartile and the third quartile, 
respectively. 
The incidence of type ≥2 BARC bleeding within 30 days was 10.8% (51 of 474 patients; 
TABLE 6). Patients who had type ≥2 BARC bleeding had a higher median NCDR CathPCI 
risk score compared with those with type 0 or type 1 bleeding (70 [IQR 60 - 85] vs. 65 [IQR 
50 - 75], p= 0.035). The median platelet aggregation was lower in patients with type ≥2 
BARC bleeding compared with patients with type 0 or type 1 bleeding (59.9% [IQR 1.5% - 
83.8%] vs. 76.9% [IQR 48.0% - 91.1%], p= 0.005). As shown in TABLE 6, the first platelet 
aggregation quartile had a higher frequency of type ≥2 BARC bleeding within 30 days 
compared with the fourth quartile and the third quartile, respectively. Clopidogrel-naïve 
patients did not have a significantly different incidence of type ≥2 BARC bleeding compared 
with those already on a clopidogrel maintenance dose (10.7% vs. 10.9%, p= 0.932). The 
frequency of type ≥2 BARC bleeding complications over time is depicted in FIGURE 4.  
The first quartile of platelet aggregation predicted type ≥2 BARC bleeding in the multivariate 
Cox regression, when adjusted for NCDR the other included variables (TABLE 7). The NCDR 
risk score did also significantly predict type ≥2 BARC bleeding complications in the model, 
adjusted for the other included variables. ROC curve analysis showed a significant correlation 
between type ≥2 BARC bleeding and on-treatment platelet aggregation, with an area under 
the curve of 0.62 (95% confidence interval [CI] 0.54 - 0.70, p= 0.005). The optimal cutoff 
was 76.7% platelet aggregation, with 71% sensitivity and 51% specificity. The incidence of 
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type ≥2 BARC bleeding was 14.7% (36 of 245 patients) in patients with ≤76.7% platelet 
aggregation and 6.6% (15 of 229 patients) in patients with >76.7% platelet aggregation 
(relative risk 2.2, 95% CI 1.3 - 4.0, p= 0.004).  
As listed in TABLE 6, the incidence of ARMYDABLEEDS-defined bleeding within 30 days 
was 4.6% (22 of 474 patients). Patients who had an ARMYDA-BLEEDS-defined bleeding 
event within 30 days had an equal median NCDR CathPCI risk score compared with those 
without bleeding (65 [IQR 60 to 76.25] vs. 65 [IQR 50 to 80], p=1.00). Median platelet 
aggregation was lower in patients with ARMYDABLEEDS-defined bleeding compared with 
patients without bleeding (50.1% [IQR 31.8% - 75.3%] vs. 76.4% [IQR 47.0% - 91.0%], p= 
0.016). As shown in TABLE 6, patients in the lowest platelet aggregation quartile had a higher 
occurrence of ARMYDABLEEDS-defined bleeding within 30 days compared with the third 
quartile and the fourth quartile, respectively. ARMYDA-BLEEDS-defined bleeding did not 
differ significantly between clopidogrel-naïve patients and those already on clopidogrel 
maintenance treatment (4.2% vs. 5.8%, p= 0.429). The cumulative incidence of ARMYDA-
BLEEDS-defined bleeding events over time is depicted in FIGURE 5.  
In the multivariate Cox regression the lowest quartile of platelet aggregation predicted 
increased risk for ARMYDA-BLEEDS-defined bleeding within 30 days, when adjusted for 
the other included variables (TABLE 7). The ROC curve analysis platelet function testing was 
able to distinguish between patients with and without ARMYDA-BLEEDS-defined bleeding, 
with an area under the curve of 0.65 (95% CI 0.54 - 0.76, p= 0.016). The optimal platelet 
aggregation cutoff was found at 74.8% platelet aggregation, with 77% sensitivity and 52% 
specificity. The incidence of ARMYDABLEEDS- defined bleeding within 30 days was 7.3% 
(17 of 233 patients) in patients with ≤74.8%platelet aggregation and 2.1% (5 of 241 patients) 
in patients with >74.8% platelet aggregation (relative risk 3.5, 95% CI 1.3 - 9.4, p= 0.007). 
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TABLE 4. Demographic characteristics 
 Characteristic 1st Quartile 
(n = 118) 
2nd Quartile 
(n = 119 
3rd Quartile 
(n = 117) 
4th Quartile 
(n = 120) 
P-
value* 
 Median [range] platelet 
aggregation 
29%  
[0-46%] 
63%  
[47-75%] 
84%  
[75-91%] 
96%  
[91-100%] 
 
    Age (years) 63.9 ± 8.9 65.0 ± 11.2 65.9 ± 11.8 65.5 ± 10.9 0.20 
 Women 28 (24%) 31 (26%) 23 (20%) 23 (19%) 0.39 
 BMI (kg/m2) 26.3 ± 5.0 26.9 ± 3.9 27.3 ± 5.4 28.7 ± 4.4 <0.001 
 Hypertension† 65 (55%) 62 (52%) 58 (50%) 73 (61%) 0.37 
 Diabetes mellitus 23 (19%) 35 (29%) 29 (25%) 32 (27%) 0.19 
 Current smokers 19 (16%) 24 (20%) 27 (23%) 21 (18%) 0.77 
 Prior myocardial infarction 33 (28%) 36 (30%) 36 (31%) 36 (30%) 0.73 
 Prior percutaneous 
coronary intervention 
25 (21%) 20 (17%) 29 (25%) 26 (22%) 0.93 
 Prior coronary bypass 20 (17%) 18 (15%) 16 (14%) 15 (13%) 0.44 
NCDR® CathPCI Bleeding Risk (61) 
 Total score (points) 63.3 ± 20.4 65.8 ± 20.1 64.3 ± 21.3 65.0 ± 21.7 0.63 
    - Low risk (<25) - 1 (1%) 5 (4%) 3 (3%) 0.25 
    - Medium risk (26-65) 66 (56%) 64 (54%) 63 (54%) 64 (53%) 0.69 
    - High risk (>65) 52 (44%) 54 (45%) 49 (42%) 53 (44%) 0.99 
Medication 
 Clopidogrel LD (mg)      
     150  - 1 (1%) 1 (1%) 1 (1%) 0.32 
     300  51 (43%) 59 (50%) 60 (51%) 64 (53%) 0.12 
     450  - 1 (1%) 2 (2%) 2 (17%) 0.50 
     600  22 (19%) 22 (18%) 22 (19%) 28 (23%) 0.38 
     800  - 1 (1%) - - N/A 
 Time (hours) from LD to 
coronary angiography 
47 [24 / 97] 69 [35 / 122] 45 [22 / 100] 27 [16 / 52] <0.001 
 Time (hours) from last dose 
to coronary angiography 
4.5 [2.5 / 6.0] 5.0 [3.0 / 6.0] 5.5 [3.5 / 6.5] 5.0 [3.0 / 7.0] 0.107 
 Clopidogrel maintenance 
treatment (months) 
3 [1 / 3] 3 [0 / 3] 3 [0 / 3] 3 [1 / 3]  
 Lipid-lowering drugs 102 (86%) 102 (86%) 96 (82%) 102 (85%) 0.75 
 Proton pump inhibitors 16 (14%) 23 (19%) 21 (18%) 16 (13%) 0.96 
 Fondaparinux 43 (36%) 47 (39%) 49 (42%) 52 (43%) 0.28 
 Bivalirudin - - 2 (2%) 1 (1%) 1.00 
Data are expressed by number (percentage) for categorical variables, and as mean ±SD or median [25th / 
75th percentile] for continuous variables. Quartiles were established for the percentage of platelet 
aggregation measured by adenosine diphosphate-induced single-platelet aggregation. 
Abbreviations: LD, loading dose. 
*Comparison between quartile 1 and quartile 4. †Defined as documented and treated hypertension. 
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TABLE 5. Procedural characteristics 
 Characteristic 1st Quartile 
(n = 118) 
2nd Quartile 
(n = 119 
3rd Quartile 
(n = 117) 
4th Quartile 
(n = 120) 
P-
value* 
 Median [range] platelet 
aggregation 
29%  
[0-46%] 
63%  
[47-75%] 
84%  
[75-91%] 
96%  
[91-100%] 
 
Procedural characteristics 
 Femoral approach 114 (97%) 112 (94%) 108 (92%) 110 (92%) 0.11 
 Radial approach 4 (3%) 7 (6%) 9 (8%) 10 (8%) 0.11 
 Vascular closing device 58 (49%) 57 (48%) 64 (55%) 68 (57%) 0.25 
 PCI performed 70 (59%) 56 (47%) 64 (55%) 75 (63%) 0.62 
 GP IIb/IIIa inhibitors 14 (12%) 9 (8%) 16 (14%) 14 (12%) 0.96 
Laboratory data 
 Platelet count, x109/L 220.9 ± 59.5 220.4 ± 51.4 219.1 ± 69.3 221.1 ± 53.8 0.98 
 Hemoglobin (g/L) 138.0 ± 16.4 136.8 ± 16.4 138.6 ± 16.1 140.8 ± 16.5 0.19 
 Hematocrit 0.39 ± 0.04 0.38 ± 0.05 0.38 ± 0.05 0.40 ± 0.04 0.16 
 Creatinine clearance (ml/min)† 86.6 ± 25.9 83.1 ± 29.2 87.5 ± 35.0 93.3 ± 31.7 0.11 
 Diagnosis at discharge      
 STEMI 2 (2%) 2 (2%) 5 (4%) 11 (9%) 0.01 
 NSTEMI/unstable angina 68 (58%) 66 (55%) 67 (57%) 68 (57%) 0.88 
 Stable angina 36 (31%) 31 (26%) 31 (26%) 34 (38%) 0.71 
 Unspecific chest pain 5 (4%) 12 (10%) 6 (5%) 3 (3%) 0.50 
 Other‡ 6 (5%) 6 (5%) 8 (7%) 4 (3%) 0.54 
Data are expressed by number (percentage) for categorical variables, or as mean ±SD for continuous variables. 
Quartiles were established for the percentage of platelet aggregation measured by adenosine diphosphate-
induced single-platelet aggregation. Abbreviations: GP, glycoprotein; PCI, percutaneous coronary 
intervention; STEMI, ST-elevation myocardial infarction; NSTEMI, non ST-elevation myocardial infarction. 
*Comparison between quartile 1 and quartile 4. †Estimated with Cockcroft-Gault equation. ‡Includes heart 
failure, aortic stenosis, arterio-ventricular block, and tachycardia. 
 
 
TABLE 6. Quartile distribution of bleeding events. 
 Total 
(n = 474) 
1st Quartile 
(n = 118) 
2nd Quartile 
(n = 119) 
3rd Quartile 
(n = 117) 
4th Quartile 
(n = 120) 
P-
value* 
Median [range] of platelet 
aggregation 
75%  
[0-100%] 
29%  
[0-46%] 
63%  
[47-75%] 
84%  
[75-91%] 
96%  
[91-100%] 
 
BARC bleeding       
Type 1 76 (16%) 28 (24%) 20 (17%) 16 (14%) 12 (10%) <0.01 
Type 2 39 (8%) 14 (12%) 12 (10%) 5 (4%) 8 (7%) 0.17 
Type 3a 5 (1%) 3 (3%) 1 (1%) 1 (1%) - 0.12 
         3b 5 (1%) 2 (2%) 1 (1%) 2 (2%) - 0.25 
         3c 1 (1%) - - 1 (1%) - N/A 
Type 4 1 (1%) 1 (1%) - - - 0.50 
Type 5a - - - - - N/A 
         5b - - - - - N/A 
≥ Type 1 127 (27%) 48 (41%) 34 (29%) 25 (21%) 20 (17%) <0.001 
≥ Type 2 51 (11%) 20 (17%) 14 (12%) 9 (8%)† 8 (7%) 0.014 
ARMYDA-BLEEDS defined bleeding 
Major TIMI bleeding  6 (1%) 4 (3%) 1 (1%) 1 (1%) - 0.06 
Entry site complications 
      >10 cm hematoma 14 (3%) 5 (4%) 4 (3%) 3 (3%) 2 (2%) 0.28 
      Pseudoaneurysm 6 (1%) 1 (1%) 3 (3%) - 2 (2%) 1.0 
      AV-fistula - - - - - N/A 
Combined end point‡ 22 (5%) 10 (8%) 7 (6%) 3 (3%)§ 2 (2%) 0.016 
Data are expressed by number (percentage) for categorical variables, or as mean ±SD for continuous variables. 
Quartiles were established for the percentage of platelet aggregation measured by adenosine diphosphate-
induced single-platelet aggregation. Abbreviations: AV, arterio-venous; TIMI, Thrombolysis in Myocardial 
Infarction. 
* Comparison between quartile 1 and quartile 4  †p = 0.031 (quartile 1 vs quartile 3). ‡ >10cm hematoma, 
pseudo-aneurysm, AV-fistula, or major TIMI bleeding (4 patients had 2 events each). § p = 0.048 (quartile 1 vs 
quartile 3). 
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TABLE 7. Cox regression analysis 
             Univariate analysis    Multivariate analysis 
 OR (95% CI) P-value OR (95% CI) P-value 
BARC ≥ type 2 bleeding     
 Quartile 1 (platelet aggregation) 1.99 (1.14 – 3.50) 0.016 2.08 (1.19 – 3.66) 0.011 
 NCDR risk score (10-point increase)* 1.17 (1.03 – 1.33) 0.014 1.18 (1.03 – 1.35) 0.014 
 Fondaparinux 1.23 (0.71 – 2.14) 0.457 1.04 (0.59 – 1.83) 0.902 
 Periprocedural GP IIb/IIIa inhibitors 1.26 (0.57- 2.79) 0.572 1.19 (0.54 – 2.65) 0.666 
 Diabetes 0.54 (0.26 – 1.15) 0.112 - - 
 Bivalirudin 0.05 (0.0 – 2.01x106) 0.698 - - 
 Angioseal 1.11 (0.64 – 1.93) 0.71 - - 
ARMYDA-BLEEDS defined bleeding 
 Quartile 1 (platelet aggregation) 2.55 (1.10 – 5.89) 0.034 2.54 (1.10 – 5.90) 0.029 
 NCDR risk score (10-point increase) * 1.01 (0.83 – 1.24) 0.900 1.02 (0.82 – 1.26) 0.868 
 Fondaparinux 1.02 (0.44 – 2.40) 0.956 1.02 (0.42 – 2.50) 0.964 
 Periprocedural GP IIb/IIIa inhibitors 1.77 (0.60 – 5.22) 0.303 1.74 (0.59 – 5.14) 0.318 
 Diabetes 0.47 (0.14 – 1.58) 0.220 - - 
 Bivalirudin 0.05 (0.0 – 7.1x108) 0.801 - - 
 Angioseal 0.63 (0.27 – 1.46) 0.28 - - 
* The NCDR Cath PCI Bleeding Risk Score (61) is based on the following variables: STEMI, age, BMI, Previous PCI, chronic 
kidney disease, shock, cardiac arrest <24h, gender, hemoglobin levels, and PCI status. 
FIGURE 4. Frequency of ≥ type 2 BARC bleeding  
over time according to platelet aggregation quartiles. 
 
FIGURE 5. Frequency of ARMYDA-BLEEDS 
defined bleeding over time according to platelet 
aggregation quartiles. 
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4.3 STUDY III 
The final study cohort included 40 NSTEMI patients and 20 SCAD controls (FIGURE 6). 
Baseline characteristics are shown in TABLE 8. Diabetes mellitus was significantly more 
common in the NSTEMI group. The median GRACE risk score (66) of the NSTEMI patients 
was 121.5 (IQR 105-142) with 25% (n = 10) having a high score (> 140), 45% (n = 18) 
having an intermediate score (109-140), and 30% (n = 12) having a low score. Of the 
included NSTEMI patients, 75% (n = 30) underwent coronary angiography during their 
primary admission. Of these, 73% (n = 22) underwent PCI and one patient was referred for 
coronary artery by-pass surgery. The median time from ticagrelor LD to coronary 
angiography was 27 hours (IQR 23.75 - 48 hours).  
The pharmacokinetic parameters of ticagrelor and its active metabolite AR-C124910XX are 
shown in TABLE 9. None of the variables differed statistically significant between the 
NSTEMI patients and the SCAD controls, including the primary endpoint median Tmax for 
ticagrelor (2 hours [1 – 3]) vs. 2 hours [2 – 3], p= 0.393). FIGURE 7 shows box plots of the 
ticagrelor concentrations. The AR-C124910XX plasma concentrations after the ticagrelor LD 
are depicted in FIGURE 8.  
The pharmacodynamic response is shown in TABLE 10 and FIGURE 9. Both the NSTEMI 
patients and the SCAD controls had a fast onset of platelet inhibition by ticagrelor, with 15% 
(6 patients) and 10% prevalence (2 patients) of HPR at 1 hour (p= 0.707), and 2.5% (1 
patient) and 0% at 2 hours (p = 1.0), respectively. The median platelet aggregation units were 
significantly higher in the NSTEMI group at 3 hours post the ticagrelor LD (p= 0.048). 
Furthermore, the median aggregation units was borderline statistically significantly higher in 
NSTEMI patients at 5 and 6 hours post the ticagrelor LD (p = 0.056, and p= 0.051, 
respectively), but without any prevalence of HPR.  
There was a significant correlation between the ticagrelor concentrations and platelet 
aggregation during the first 6 hours after the 180 mg ticagrelor LD with data from all patients 
(Spearman’s correlation coefficient −0.549, p< 0.001, TABLE 11). There were also significant 
correlations between the ticagrelor concentrations and platelet aggregation when assessed at 
one, two, three, and four hours post the 180-mg ticagrelor LD, with the strongest correlation 
at 1 hour. No serious adverse events occurred during the sampling period, but one NSTEMI 
patient had cardiogenic shock at study inclusion and underwent PCI within 2 hours.  
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Table 8. Demographic characteristics 
Patient Characteristics 
 
NSTEMI patients 
(n=40) 
SCAD controls  
(n=20) 
p  
value 
Clinical Parameters    
     Age, years 64.9 ± 10.7 65.9 ± 10.5 0.732 
     Male gender 28 (70%) 16 (80%) 0.541 
     BMI, kg/m2 27.3 ± 3.9 26.1 ± 2.7 0.169 
     Current Smoker 9 (23%) 3 (15%) 0.734 
     Diabetes mellitus 16 (40%) 2 (10%) 0.019 
     Hypertension 23 (58%) 11 (55%) 1.0 
     Prior MI 5 (13%) 5 (25%) 0.278 
Prior PCI 5 (13%) 9 (45%) 0.009 
     Prior CABG 3 (7.5%) 0 (0%) 0.544 
Prior non-hemorrhagic stroke 2 (5%) 0 (0%) 0.548 
COPD 2 (5%) 0 (0%) 0.548 
Laboratory data    
     Platelet count, x109/L 225.0 ± 51.4 225.0 ± 48.6 0.994 
     Hemoglobin, g/L 145.2 ± 13.0 143.9 ± 17.2 0.750 
     eGFR*, ml/min 94.3 ± 34.0 83.9 ± 25.5 0.233 
Medication at inclusion    
     Cholesterol lowering medication 14 (35%) 19 (95%) <0.001 
     Aspirin 39 (97.5%) 20 (100%) 1.0 
Data are presented as mean ± standard deviation for continuous variables, and as frequency (percentage) for 
categorical variables. Continuous variables were tested with the Student´s t-test and categorical variables with 
the Fisher’s exact test.  
*eGFR was calculated by using Cockcroft-Gault formula. 
Abbreviations: BMI = body mass index; CABG = coronary artery bypass graft; COPD = Chronic obstructive 
pulmonary disease; EVF = erythrocyte volume fraction; eGRF = estimated glomerular filtration rate; MI = 
myocardial infarction; NSTEMI = non-ST elevated myocardial infarction; SCAD = stable coronary artery 
disease. 
 
 
 
Table 9. Pharmacokinetic parameters 
 NSTEMI patients 
(n=40) 
SCAD controls 
(n=20) 
p value 
Ticagrelor    
    Cmax (ng/mL) 1285 (1006 – 2610) 1230 (958 – 1720) 0.819 
    AUC0-6h (ng x h/ml) 4561 (3258 – 5640) 3971 (3494 – 4960) 0.703 
    Tmax (hours) 2.0 (1.0 – 3.0) 2.0 (2.0 – 3.0) 0.393 
AR-C124910XX    
    Cmax (ng/mL) 308 (235 – 399) 267 (245 – 355) 0.526 
    AUC0-6 (ng x h/ml) 1170 (868 – 1601) 987 (757 – 1225) 0.187 
    Tmax (hours) 3 (2.0– 4.0) 3 (2.5 – 4.0) 0.289 
Values are expressed as median with IQR, 25th – 75th percentile. Interference was tested with the Mann-
Whitney U test. Abbreviations: AUC0-6h = Area under the curve from 0 hours to 6 hours; Cmax = 
maximum (peak) plasma concentration; NSTEMI = non-ST elevated myocardial infarction; SCAD = stable 
coronary artery disease; Tmax = Time to peak plasma concentration. 
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Table 10. Pharmacodynamic response 
Pharmacodynamic Parameters NSTEMI  
(n=40) 
SCAD controls 
 (n=20) 
P-value 
Sample 0h    
    Platelet aggregation (AU) 71.5 (52.5 – 84.0) 66.5 (57.5 – 72.0) 0.578 
Sample 1h        
    Platelet aggregation (AU) 17.0  (15 – 26.5) 25.5 (17.5 – 32.0) 0.075 
    HPR 6 (15%) 2 (10%) 0.707 
Sample 2h    
    Platelet aggregation (AU) 17.0 (13.5 – 23.0) 17.5 (12.5 – 22.0) 0.567 
    HPR 1 (3%) 0 (0%) 1.0 
Sample 3h    
    Platelet aggregation (AU) 17.0 (13.0 – 22.0) 13.0 (9.5 – 17.5) 0.048 
    HPR 0 (0%) 0 (0%) N/A 
Sample 4h    
    Platelet aggregation (AU) 15.5 (12.5 – 23.0) 14.0 (11.5 – 15.5) 0.198 
    HPR 0 (0%) 0 (0%) N/A 
Sample 5h    
    Platelet aggregation (AU) 17.0 (14.0 – 23.0) 13.0 (11.5 – 18.0) 0.056 
    HPR 0 (0%) 0 (0%) N/A 
Sample 6h    
    Platelet aggregation (AU) 17.0 (12.0 – 23.0) 13.5 (10.0 – 16.5) 0.051 
    HPR 0 (0%) 0 (0%) N/A 
Area under the curve (AUC) 0-6h (AU x h) 132 (112 – 160) 128 (103 – 152) 0.411 
Data are presented as median (interquartile range, 25th - 75th percentile) for quantitative variables, and as 
frequency (percentage) for qualitative variables. Continuous variables were tested with the Mann-Whitney 
U-test and categorical variables were tested with the Fisher’s exact test. Abbreviations: AUC = area under 
the curve; HPR = high on-treatment platelet reactivity; NSTEMI = non-ST elevated myocardial infarction; 
SCAD = stable coronary artery disease.  
  
Table 11. Correlation between ticagrelor concentrations and platelet aggregation 
 Total cohort 
(n=60) 
NSTEMI  
(n=40) 
SCAD controls 
 (n=20) 
Sample 0h    
Correlation coefficient* N/A N/A N/A 
P value N/A N/A N/A 
Sample 1h        
Correlation coefficient −0.666 −0.505 −0.827 
P value <0.001 <0.001 <0.001 
Sample 2h    
Correlation coefficient −0.391 −0.360 −0.384 
P value 0.002 0.023 0.095 
Sample 3h    
Correlation coefficient −0.364 −0.232 −0.533 
P value 0.004 0.150 0.016 
Sample 4h    
Correlation coefficient −0.296 −0.256 −0.248 
P value 0.021 0.111 0.291 
Sample 5h    
Correlation coefficient −0.023 0.034 −0.128 
P value 0.862 0.837 0.592 
Sample 6h    
Correlation coefficient −0.059 0.100 −0.147 
P value 0.654 0.540 0.536 
Samples 1,2,3,4,5, and 6 hours    
Correlation coefficient −0.549 −0.505 −0.636 
P value <0.001 <0.001 <0.001 
*Correlation analyses were performed with Spearman´s correlation. 
Abbreviations: NSTEMI = non-ST elevated myocardial infarction; SCAD = stable coronary artery disease; 
N/A = Not applicable 
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Figure 6. Study inclusion chart 
NSTEMI indicates non ST-segment elevation myocardial infarction. SCAD indicates stable coronary artery 
disease. 
 
  
Figure 7. Ticagrelor concentrations 
Ticagrelor concentrations at the different sampling time 
points shown in a boxplot. Center lines represent median 
and boxes 25th and 75th percentile  
 
Figure 8.  AR-C124910XX concentrations 
Boxplot depicting concentrations of the active metabolite 
AR-C124910XX. Center lines represent median and boxes 
25th and 75th percentile. 
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Figure 9. Pharmacodynamic response 
Individual values of platelet reactivity at 0, 1, 2, 3, 4, 5, and 6, hours post the 180 mg ticagrelor LD, as assessed 
with ADP-induced multiple electrode aggregometry and shown in aggregation units (AU). The high on-
treatment platelet reactivity (HPR) threshold is depicted as 46 AU. There were no significant differences in HPR 
at all time-points between the groups, whereas the AU was just significantly higher in NSTEMI patients at 3 
hours  (p = 0.048).  
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4.4 STUDY IV 
A total of 95 STEMI patients were included in the study, which represents 31% of the 302 
patients who presented with STEMI at the cardiac catheterization laboratories on the 
participating hospitals during the study period. The final study cohort consisted of 82 patients 
who were randomly assigned to receive either methylnaltrexone (n= 43) or placebo (n= 39), 
as shown in FIGURE 10.  
The baseline characteristics were well balanced between the groups, as shown in TABLE 12. 
Procedural characteristics are listed in TABLE 13. The median time from the ticagrelor LD to 
study intervention and the median additional morphine administered did not differ 
significantly between the methylnaltrexone group and the placebo group. 
As shown in TABLE 14 and FIGURE 11, the prevalence of HPR at two hours (primary outcome 
variable) did not differ significantly between patients randomized to methylnaltrexone 
compared to placebo (54% vs. 51%, p=0.84). Assessment with VASP showed no significant 
difference in platelet reactivity index (PRI%) between methylnaltrexone and placebo at 
baseline (p= 0.29), at one (p= 0.066), and at two hours (p= 0.38) after the study intervention, 
respectively.   
The drug concentration analyses of morphine, ticagrelor, and the main active metabolite of 
ticagrelor, AR-C124910XX, are shown in TABLE 15 including comparisons between the 
groups. Plasma morphine concentrations (p= 0.94) did not differ significantly between the 
groups.  Administration of methylnaltrexone when compared with placebo did not effect in a 
significant difference in ticagrelor or AR-C124910XX concentration at any of the time-
points.  
There was no significant difference in patient self-estimated pain between patients receiving 
methylnaltrexone and placebo at baseline (median pain level (IQR) 3 (2-5) vs. 2 (1-5, 
p=0.092) or at one (0 (0-2) vs. 2 (2-5), p = 0.36) or two hours after the study intervention (0 
(0-1) vs. 0 (0-1), p = 0.28). Moreover, the difference (Δ) in pain between baseline and 1 or 2 
hours did not differ significantly between the groups (2 (0.4) vs. 1 (0-3), p = 0.085 and 2 (0-
5) vs. (2 (0-4), p=0.25, respectively). 
Adverse events within 48 hours of study inclusion were registered. Life threatening 
arrhythmia, defined as need for cardiopulmonary resuscitation, or non-sustained ventricular 
tachycardia did not differ significantly between patients receiving methylnaltrexone or 
placebo (12% vs. 3%, p= 0.20; 60% vs. 49%, p=0.29). Death of any cause occurred in 5% of 
patients with methylnaltrexone compared with none of the placebo patients (p= 0.50), while 
the corresponding incidences of peri/postprocedural pulmonary edema were 0% and 6% 
(p=0.24), respectively. No patients experienced stent thrombosis, stroke, or bleedings other 
than minor access site.  
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TABLE 12. Demographic characteristics 
Characteristic 
 
Placebo 
(n=39) 
Methylnaltrexone  
(n=43) 
p  
value 
Demographic/clinical    
Age, yr 69 (58, 77) 64 (60, 73) 0.45 
Age >75 yr  12 (31) 7 (16) 0.12 
Male gender  34 (87) 35 (81) 0.47 
BMI  26.9 (25.0 - 29.1) 26.3 (24.1 - 28.1) 0.27 
BMI > 25  29 (74) 27 (63) 0.26 
Hypertension  17 (44) 22 (51) 0.49 
Diabetes Mellitus  6 (15) 6 (14) 0.85 
Dyslipidaemia  8 (21) 9 (21) 0.96 
Current smoker  5 (13) 13 (30) 0.06 
Prior AMI  4 (10) 4 (9) 1.00 
Prior PCI  4 (10) 4 (9) 1.00 
Prior CABG  0 (0) 1 (2) 1.00 
Prior non-haemorrhagic stroke  0 (0) 2 (5) 0.50 
Peripheral arterial disease 1 (3) 1 (2) 1.00 
Chronic renal failure  2 (5) 2 (5) 1.00 
COPD  2 (5) 4 (9) 0.68 
Laboratory data    
Creatinine, µmol/L 83 (72 - 98) 82 (74 - 98) 0.92 
eGFR*, ml/min 72 (59 - 84) 73 (58 - 82) 0.97 
Hemoglobin g/L 147 (134 - 154) 147 (134 - 155) 0.88 
Platelet count, x10^9 248 (201 - 288) 247 (208 - 285) 0.94 
Prehospital medication    
Morphine dose, mg 6 (5 - 10) 6 (5 - 10) 0.63 
Ondansetrone  8 (21) 3 (7) 0.07 
Metoklopramide  3 (8) 4 (9) 0.79 
Continuous variables are described as median (IQR) and were tested with the Wilcoxon rank-sum test. Categorical 
variables are described as no. (%) and were tested the χ2-test, or if needed with Fisher’s exact test.  
*eGFR was calculated using the Cockcroft-Gault formula. 
Abbreviations: AMI = acute myocardial infarction;BMI = body mass index; CABG = coronary artery bypass graft; 
COPD = Chronic obstructive pulmonary disease; eGRF = estimated glomerular filtration rate; IQR = Interquartile 
range; PCI = Percutaneous coronary intervention. 
TABLE 13. Procedural characteristics 
Procedural characteristics Placebo 
(n=39) 
Methylnaltrexone  
(n=43) 
p  
value 
Clinical presentation    
Inferior STEMI  18 (46) 20 (47) 0.97 
Systolic blood pressure, mmHg 140 (125 - 155) 135 (120 - 152) 0.58 
Cardiogenic shock  0 (0) 1 (2) 1.00 
Pulmonary edema  2 (6) 0 (0) 0.24 
Procedural aspects    
Time from ticagrelor LD to study 
intervention, min 41 (31 - 50) 45.5 (37 - 60) 0.16 
GP IIb/IIIa inhibitors  1 (3) 2 (5) 1.00 
Heparin dose, IU 5000 (3000 - 8000) 5000 (3000 - 8000) 0.75 
Enoxaparin  1 (3) 0 (0) 0.48 
Bivalirudin  16 (41) 18 (42) 0.94 
Thrombus aspiration  3 (8) 6 (14) 0.49 
No. of stents used 1 (1, 2) 1 (1, 2) 0.92 
Additional procedural medication    
Ondansetron  3 (8) 4 (9) 1.00 
Metoklopramid  8 (21) 8 (19) 1.00 
Morphine dose, mg 0 (0 - 3) 2 (0 - 5) 0.25 
Continuous variables are described as median (IQR) and were tested with the Wilcoxon rank-sum test. 
Categorical variables are described as no. (%) and were tested the χ2-test, or if needed with Fisher’s exact test.  
Abbreviations: GP = glycoprotein; IU = international unit; IQR = Interquartile range; STEMI = ST-segment 
elevation myocardial infarction;; 
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TABLE 14. Pharmacodynamic evaluation 
 Placebo 
(n=39) 
Methylnaltrexone  
(n=43) 
p 
value 
Platelet function testing    
PRI% at baseline  86.4 (67.0 - 92.8) 90.3 (68.7 -93.8) 0.29 
PRI% at 1h  59.0 (27.9 - 89.3) 84.9 (43.0 -92.6) 0.066 
PRI% at 2h  57.8 (20.9 - 84.1) 63.2 (24.3 - 89.2) 0.38 
ΔPRI% 0h-1h  14.9 (-1.40 - 39.0) 3.32 (-0.72 - 23.0) 0.18 
ΔPRI% 0h-2h  16.4 (-0.04 - 45.1) 11.6 (0.82 - 37.9) 0.73 
HPR* at baseline  
30 (83) 38 (90) 0.35 
HPR at 1h 18 (53) 29 (72) 0.082 
HPR at 2h 18 (51) 21 (54) 0.84 
Continuous variables are described as median (IQR) and were tested with the Wilcoxon rank-sum test. 
Categorical variables are described as no. (%) and were tested the χ2-test, or if needed with Fisher’s exact test. 
The difference (Δ) in PRI% between the time points 0-1h and 0-2h is presented. Positive values suggest 
decreased PRI% levels. 
*HPR is defined as PRI ≥ 50%. 
Abbreviations: HPR= High on-treatment platelet reactivity; IQR= Interquartile range; PRI= Platelet Reactivity 
Index.  
 
 
TABLE 15. Pharmacokinetic evaluation 
 Placebo 
(n=39) 
Methylnaltrexone  
(n=43) 
p 
value 
Drug concentration analyses (ng/mL)    
Morphine at baseline 12.8 (9.37 - 22.0) 13.2 (6.27 - 28.5) 0.94 
Ticagrelor at baseline 0 (0 - 33.1) 0 (0 - 36.6) 0.42 
Ticagrelor at 1h 41.1 (0 - 571) 39.2 (0 - 154) 0.41 
Ticagrelor at 2h 88.3 (15.2 - 820) 105 (0 - 518) 0.88 
Δticagrelor 1h-0h 22.7 (0 - 211) 27.5 (0 - 101) 0.81 
Δticagrelor 2h-0h 40.2 (0 - 432) 94.6 (0 - 289) 0.57 
AR-C124910XX at 0h 0 (0 - 0) 0 (0 - 0) 0.94 
AR-C124910XX at 1h 0 (0 - 52.9) 0 (0 - 6.81) 0.17 
AR-C124910XX at 2h 5.49 (0 - 104) 6.14 (0 - 55.9) 0.95 
ΔAR-C124910XX 1h-0h 0 (0 - 46.7) 0 (0 - 6.81) 0.15 
ΔAR-C124910XX 2h-0h 2.63 (0 - 94.8) 6.14 (0 - 54.1) 0.71 
Continuous variables are described as median (IQR) and were tested with the Wilcoxon rank-sum test. 
Categorical variables are described as no. (%) and were tested the χ2-test, or if needed with Fisher’s exact test. 
The lower level of detection for ticagrelor and AR-C124910XX concentrations were 5 ng/mL. 
The difference (Δ) in ticagrelor and AR-C124910XX concentrations, respectively, between the time points 0-1h 
and 0-2h is presented. Positive values suggest increased concentrations.  
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FIGURE 10. Enrollment and randomization.  
Patients who presented with ST-segment elevation myocardial infarction at the respective cardiac catheterization 
laboratories were considered for study inclusion. The figure show the number of patients enrolled in the study 
and randomized. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 11. Prevalence of high on-treatment platelet reactivity.  
Defined as ≥ 50% PRI with the VASP assay before inclusion, 1 hour, and 2 hours after study intervention. 
Differences in the prevalence in HPR were tested with the χ2-test. 
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5 DISCUSSION 
The major findings in this thesis were as follows. Patients with impaired response to 
clopidogrel, i.e. HPR, according to platelet function testing with Plateletworks® shortly 
before coronary angiography/PCI had a significantly higher incidence of myocardial 
infarction within 3 months. Those in the lowest quartile of platelet aggregation with the 
Plateletworks® assay had a significantly higher incidence of bleeding within 30 days, 
according to two relevant bleeding definitions. An oral LD of 180 mg ticagrelor resulted in an 
early maximal drug concentration, in median at two hours, and a rapid onset of platelet 
inhibition both in NSTEMI patients and patients with SCAD. Randomized intravenous 
administration of the peripheral opioid antagonist methylnaltrexone did not significantly 
improve the delayed antiplatelet effect or drug uptake after a 180 mg ticagrelor in morphine 
treated patients with STEMI. 
5.1 PREDICTIVE VALUE OF THE PLATELETWORKS® ASSAY 
In Study I, patients with HPR, according to platelet function testing with the Plateletworks® 
assay, had a significantly higher incidence of myocardial infarction within three months after 
coronary angiography compared with those with an adequate response to clopidogrel. 
Moreover, the patients with HPR had a higher BMI and also a higher incidence of 
rehospitalization due to cardiovascular events within three months. The optimal cut-off for 
the prediction of myocardial infarction within three months was found to be 82.3% platelet 
aggregation with a rather modest AUC of 0.60 in the ROC curve analysis. The underlying 
sensitivity of 66.7% and specificity of 60.9% were also not very high. To our knowledge, the 
only previous study establishing a cut-off for Plateletworks® for prediction of the risk for 
ischemic cardiovascular events found a similar optimal cut-off at 80.5%. The authors found a 
similar sensitivity and specificity of 63% and 58.5%, respectively, and an AUC of 0.61 in 
their ROC curve analysis (34). Moreover, the incidence of HPR was in that study very similar 
to Study I (43.2% vs. 39.9%) (34). These findings might indicate reproducibility of the 
Plateletworks® assay, but with a rather modest predictability in both studies.  In contrast to 
that study, there was only a non-significant tendency (p= 0.09) in Study I of patients in the 
HPR group with the combined end-point of all-cause death, nonfatal myocardial infarction, or 
stent thrombosis (34). This might be due to a type I error, as the other study included more 
patients (n=606), or possibly unknown confounding. It might also be due to the shorter 
follow-up of our study (3 months vs. 1 year). However, we cannot exclude that it is due to a 
failure of the Plateletworks® assay to properly identify all HPR patient at risk for recurrent 
cardiovascular events, especially since combined endpoints often are beneficial to use in 
smaller studies.  
Study I had a significant higher ratio of patients who underwent PCI in the HPR group. The 
PCI procedure may in this unselected cohort indicate a more severe coronary disease among 
the HPR patients, which have had an impact on the risk for myocardial infarction. As the 
incidence of myocardial infarction within three months did not differ between patients who 
underwent PCI and those who underwent coronary angiography without PCI, the correlation 
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between HPR and myocardial infarction is Study I is likely not caused by the different rate of 
PCI. Moreover, the incidence of HPR was not significantly different in patients undergoing 
elective PCI patients, compared to acute PCI patients (45.1% vs. 44.8%; p= 0.96). We did not 
use stent thrombosis as a primary end-point as only 56% of the patients in Study I underwent 
PCI.   
In Study II, we assessed the predictive ability of the Plateletworks® assay with regards to 
bleeding. This was proven successful, and we were able to show a significant correlation with 
bleeding events using two relevant definitions (BARC ≥ type 2, ARMYDA-BLEEDS). 
Conversely, the abovementioned study did not find any predictive value of the Plateletworks® 
assay with regard to bleeding events (34), possibly due to a less sensitive bleeding definition. 
As the event rate in Study II was significantly higher than in Study I, we were able to adjust 
for potential confounders with a time-dependent multivariate Cox regression. In the 
regression model, we found that platelet aggregation in the lowest quartile significantly 
predicted bleeding defined with both the included bleeding definitions, when adjusted for the 
other included variables. We also established cut-offs for each bleeding definition at 76.7% 
platelet aggregation (BARC ≥ type 2) and 74.8% platelet aggregation (ARMYDA-BLEEDS). 
However, as with the cutoff established in Study I, this dichotomous approach resulted in 
only modest sensitivity and specificity.  
In Study II, we chose the BARC ≥ type 2 bleeding definition for two reasons. First, it is the 
currently recommended standardized bleeding definition. Second, this bleeding definition has 
been correlated with increased mortality in patients undergoing PCI and it is thus very 
relevant (67). It is also, however, of interest to present the incidence of BARC type 1 
bleeding. Even though it represents less serious and maybe even clinically unimportant 
bleeding, e.g. trivial nose bleeds, superficial skin bleeding etc., such events have been 
associated with premature drug cessation, which may in turn negatively impact outcome (68). 
The event rate of BARC ≥ type 2 was 11% in the overall cohort, which could be considered 
rather high. When considering this event rate, one has to take into account that BARC type 2 
bleedings is the dominant event in the combined BARC ≥ type 2. BARC type 2 includes any 
overt actionable sign of hemorrhage, which may not be so infrequent in patients who 
underwent coronary angiography using the femoral approach. However, the rate of more 
serious bleedings (BARC ≥ type 3) was 2.5%. 
In Study II, using the ARMYDA-BLEEDS bleeding definition we found a bleeding 
incidence of 4.8%, which is rather similar to the 4.6% incidence in the ARMYDA-BLEEDS 
study (32).  Furthermore, the correlation between the lowest quartile of platelet function and 
bleeding in that study was also found in Study II. Comparing the ARMYDA-BLEEDS and 
BARC ≥ type 2 bleeding definitions, the incidence was much higher with the latter. This may 
indicate that the BARC bleeding definition has a higher sensitivity than the ARMYDA-
BLEEDS bleeding definition. 
 46 
 
Another interesting finding of Study II was that most of the bleeding events occurred within 
the first 7 days after coronary angiography, regardless of definition used (FIGURE 4 and 
FIGURE 5). This may probably be due to a relatively high proportion of early procedurally 
related bleeding events but may be of interest to further evaluate in future studies. 
5.2 BLEEDING EVENTS VS. THROMBOSIS 
Like Odysseus navigated between Scylla and Charybdis, currently known pharmacological 
drugs used to avoid thrombotic events all have the drawback of increased bleeding risk. The 
therapeutic window is rather narrow, and it is not possible to use platelet inhibiting drugs to 
reduce incidence of ischemic events without increasing bleeding risk. The risk of thrombosis 
does, however, not decrease linearly with lowered on-treatment platelet reactivity. 
Conversely, the benefit with decreasing platelet reactivity with antiplatelet drugs is greatest 
when the cut-off for HPR is passed. In the case of “excessive” platelet inhibition, i.e. when 
the cut-off for low on-treatment platelet reactivity is passed, a meta-analysis has shown a 1.7-
fold higher risk for major bleeding without any further significant decrease in the incidence 
of stent thrombosis, compared with patients with platelet reactivity above LPR, but below 
HPR (69).  A schematic figure of a possible therapeutic window for the Plateletworks® assay 
is shown in FIGURE 12 including the cut-offs established in Study I and II. 
 
FIGURE 12. Thrombosis risk vs. bleeding risk on P2Y12 inhibition with clopidogrel.  
Schematic figure (not in scale) showing the cut-offs for the Plateletworks® assay established in Study I 
(82.3%), from a previously published paper (80.5%) (34), and the cut-offs for bleeding established in 
Study II (74.8% for the ARMYDA-BLEEDS bleeding definition and 76.4% for the BARC ≥ type 2 
bleeding).  
 
5.3  PLATELET FUNCTION TESTING IN CLINICAL PRACTICE 
The use of a platelet function test in clinical practice could in theory be of value to identify 
patients with HPR and thus at risk for recurrent cardiovascular events. This may theoretically 
enable an intervention that reverses this increased risk (other more potent drug, higher dose 
etc.). Adjusting treatment according to on-treatment platelet reactivity has indeed been tried 
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in patients with SCAD, however, without any significant improvement of clinical outcomes 
(70-72). Already back in 2014, the ESC guidelines stated that measurement of on-treatment 
platelet reactivity to monitor treatment response should not be routinely used but limited to 
clinical research. The guidelines did, though, state that platelet function testing “may be 
considered in specific high-risk situations (e.g. history of stent thrombosis; compliance issue; 
suspicion of resistance; high bleeding risk) (33).  
In 2016, the “Assessment of a Normal versus Tailored dose of prasugrel after stenting in 
patients Aged >75 years to Reduce the Composite of bleeding, stent Thrombosis and 
Ischemic Complications” (ANTARCTIC) study was published, where elderly patients who 
underwent PCI due to ACS were included. Despite use of monitoring of platelet function and 
treatment adjustment in this high-risk patient cohort, there was no benefit on clinical 
outcome. This further strengthens the position that routine platelet function testing to find 
patients with HPR is without value in current clinical practice. It should, however, be noted 
that platelet function testing may be considered following P2Y12 inhibitor discontinuation to 
shorten the time window to important/acute major surgery such as CABG (51). This 
approach is not discussed in detail, as it is not the subject of this thesis. Moreover, the use of a 
platelet function test to de-escalate the platelet inhibition from more potent P2Y12 inhibitors 
back to clopidogrel is possibly a future use of these assays and discussed in more detail below 
under future perspectives. 
5.4 IMPAIRED ONSET OF TICAGRELOR IN ACS 
In Study I, the time from LD of clopidogrel to coronary angiography is presented in intervals 
of <6 hours and 6-24 hours (TABLE 2), as previous studies have shown that a steady state of 
platelet inhibition is achieved at around 6 hours after a LD of clopidogrel (38, 39). With this 
in mind, it was expected that a LD of clopidogrel less than 6 hours before coronary 
angiography was significantly more common in patients with HPR. However, the frequency 
of a LD of clopidogrel 6-24 hours prior to coronary angiography was also significantly higher 
in patients with HPR, even though these patients should have steady state of platelet 
inhibition. This could possibly be explained by impaired gastrointestinal absorption, maybe 
due to morphine use in close relation with the clopidogrel administration. Data on this were, 
however, not available. In Study II, patients in the lowest quartile of platelet aggregation had 
a higher median time from the LD clopidogrel to coronary angiography, compared with the 
highest quartile (TABLE 4). This could possibly be due to a significantly higher frequency of 
STEMI in the highest quartile of platelet aggregation (TABLE 5), but as the overall rate of 
STEMI was low it might also be due to the unknown frequency of morphine administration. 
In Study III, we were able to show that NSTEMI patients not receiving opioids had an early 
uptake of ticagrelor and adequate onset of platelet inhibition, which did not significantly 
differ from the control group of patients with SCAD. We did not include NSTEMI patients 
who had been administered morphine due to its negatively impact on ticagrelor uptake in 
patients with ACS (54), as our aim was to evaluate any possible negative impact on ticagrelor 
uptake by the condition of NSTEMI in itself. During 2014, 71% of the NSTEMI patients in 
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Sweden were on ticagrelor at discharge from the hospital, according to the data available 
when we initiated Study III. Thus, it was of clinical value to demonstrate that a ticagrelor LD 
results in an early and adequate drug uptake and platelet inhibition, especially for the 
subgroup of NSTEMI patients at very high risk (hemodynamic instability/cardiogenic shock, 
refractory chest pain, life-threatening arrhythmias, mechanical complications of MI, acute 
heart failure, or recurrent dynamic ST-T-wave changes, particularly intermittent ST-
elevation), who according to guidelines should undergo invasive evaluation with coronary 
angiography within 2 hours (51).  The impact of morphine on ticagrelor uptake was 
investigated in a recent randomized trial (54), where ACS patients were randomized to 
morphine or placebo before the ticagrelor LD. Median Tmax of ticagrelor was at 2 hours in the 
placebo arm, compared with 4 hours for patients receiving morphine. Thus, the placebo arm 
of that study had a similar ticagrelor uptake as the NSTEMI and the SCAD patients of Study 
III.  
5.5 OPTIMIZING THE EARLY TICAGRELOR EFFECT IN STEMI 
Pain relief is very important in patients with ACS as reduced pain results in decreased 
sympathetic activation, and consequently lowers heart rate and blood pressure. This 
potentially positive effect of morphine has, however, not been shown to improve outcome in 
ACS patients (73). Conversely, morphine administration has in ACS patients been shown to 
correlate with negative outcome, including increased mortality (53, 74, 75). This could 
possibly be attributed to a morphine-induced impairment of uptake and effect of oral P2Y12 
inhibitors, which was also stated in the 2017 European Society of Cardiology STEMI 
guidelines (76). In Study IV, we failed to show any beneficial effect of intravenous 
administration of the peripheral opioid antagonist methylnaltrexone on the ticagrelor uptake 
and onset of effect in STEMI patients. To our knowledge, the use of methylnaltexone or any 
other opioid antagonist has not been previously studied in morphine-treated patients with 
STEMI. Thus, there is a lack of directly comparable results. However, there is a recently 
published abstract of a cross-over study on patients with coronary artery disease confirmed 
angiograpically who were randomized to either administration of intravenous 
methylnaltrexone or placebo. The patients then received intravenous morphine and shortly 
afterwards a standard 180 mg ticagrelor LD. In line with the results of Study IV, the authors 
of that study did not find any benefit of methylnaltrexone on ticagrelor uptake and antiplatelet 
effect (77). Thus, methylnaltrexone did not result in any beneficial effects neither in the more 
controlled non-acute setting of that trial, nor in the acute setting of STEMI according to 
Study IV. The strategy of administering methylnaltrexone to improve the uptake of ticagrelor 
in morphine-treated STEMI patients should not be used in clinical practice. 
In Study IV, a majority of patients had HPR two hours after the study intervention according 
to testing with VASP. This is in line with previous studies of platelet aggregation in ACS 
patients, separately presenting morphine use and platelet function testing with the VASP 
assay (37, 54).  
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5.6 LIMITATIONS 
In Study I, the variables age, the use of a clopidogrel LD, and BMI significantly predicted 
the presence of HPR. It was not deemed valuable to perform a multivariate analysis with 
myocardial infarction due the low event rate, which might be considered a limitation.  
Another limitation is that aspirin compliance or resistance was not evaluated. During 
inclusion of the study cohort for Study I and II we had an “all-comer” approach, i.e. we did 
not only include for example PCI patients. While this makes the external validity better, it 
might also have increased the risk of introducing unknown bias not controlled for. Moreover, 
in these studies only one platelet function test was used to evaluate the treatment effect of 
clopidogrel. However, in a much larger study, the Plateletworks® assay had the highest 
predictive value for a composite clinical endpoint (all-cause death, nonfatal acute myocardial 
infarction, stent thrombosis, and ischemic stroke) in a backward regression model (34). The 
assay has also been shown to correlate well with the more established laboratory based light 
transmittance aggregometry platelet function test (78). Still, it might have been of additional 
value to use parallel testing with another more established platelet function assay. 
In both Study III, and Study IV, only one platelet function test was used (MEA and VASP, 
respectively). Both these tests are more validated than Plateletworks® (36), but it may still 
have been of value to have added parallel testing with a second platelet function test. 
However, this would have, especially for Study IV, greatly reduced the feasibility of the 
studies. Moreover, the results of the platelet function tests are in study III and IV in line 
with the ticagrelor and ARC124910XX concentrations, which were analyzed with very exact 
methods. 
Study III excluded opioid-treated patients and the results are probably not applicable in 
NSTEMI patients on opioid treatment. Moreover, only P2Y12-naïve patients were and 
included and the results should possibly not be generalized to patients already on P2Y12-
inhibition. 
One limitation with Study IV was the in-hospital study inclusion and 
methylnaltrexone/placebo injection, which was chosen as the Swedish Medical Product 
Agency requires a physician asking for study participation. With this in mind, prehospital 
patient inclusion was considered too difficult to achieve. It cannot be ruled out that a 
prehospital administration of methylnaltrexone concurrent with morphine might have resulted 
in improved uptake of ticagrelor in patients with STEMI. Moreover, blood sampling was 
conducted up to two hours after study inclusion, both to facilitate feasibility of the study and 
as the primary aim was to assess the early ticagrelor effect. Nevertheless, a later significant 
difference in onset of ticagrelor effect might have occurred. This is, however, perhaps not 
very likely considering previously presented data without a significant difference between 
methylnaltrexone and placebo up to 6 hours after the ticagrelor LD (77). Moreover, in 
another recent trial a significant difference in the prevalence of HPR between morphine and 
placebo was seen already at 30 minutes with the VASP assay (54).  
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5.7 FUTURE PERSPECTIVES 
The use of a platelet function assay to guide patients toward stronger platelet inhibition has, 
as discussed above, not been consistently proven successful in reducing cardiovascular 
events. Conversely, platelet function testing has instead been suggested useful in “de-
escalating” the platelet function treatment in ACS patients from a newer P2Y12 inhibitor 
back to clopidogrel during the phase of maintenance treatment. After de-escalation back to 
clopidogrel, platelet function testing may be used to find presence of HPR or not. The 
hypothesis is that the need for stronger P2Y12 inhibition is greater early after stenting and 
there is evidence that around 80% of the stent thromboses occur within the first month after 
coronary stenting (79). This strategy of de-escalating P2Y12 treatment and then evaluating 
the prevalence with HPR using platelet function testing is currently being investigated in a 
large ongoing trial (80). 
Although not the scope of this thesis, the approach of deciding the type of P2Y12 treatment 
on the basis of genetic testing with focus on the metabolism of clopidogrel should also be 
mentioned in this context. P2Y12 treatment according to genetic testing was in a recently 
published study found to reduce the incidence of a composite endpoint within one year 
including both ischemic events (cardiovascular death, non-fatal myocardial infarction, and 
non-fatal stroke) and bleeding events (BARC type 3 or higher) compared with patients on 
“standard care” (81). This approach is interesting, although the “standard care” arm of ACS 
patients in that study had a rather high frequency of clopidogrel treatment (50.7%), even 
though the benefit of ticagrelor over clopidogrel is well established in patients with ACS (24) 
and indeed recommended in European guidelines in the absence of contraindications (11). As 
ticagrelor was more frequently used in the genotype-guided group, simple swapping from 
clopidogrel to ticagrelor instead of genetically testing may possibly have the same effect, but 
this is a subject for future studies. There is an interesting ongoing study (NCT01742117) 
evaluating the role of genetic testing in SCAD patients, where clopidogrel is still used today. 
The investigators use genetic testing to identify patients with CYP2C19 loss-of-function and 
swap these patients to ticagrelor.  That study will provide very interesting data on the use of 
genetic testing to guide P2Y12 inhibitor treatment.  
The optimal way to counteract the morphine-induced delay in ticagrelor among STEMI 
patients needs to be evaluated using other strategies than intravenous methylnaltrexone in 
further studies. Possible strategies may include the use of the novel i.v. P2Y12 receptor 
inhibitor cangrelor to overcome early HPR (25) although to our knowledge, there are not 
clinical studies directly comparing this strategy with standard ticagrelor use. Possible 
alternative interventions include the addition of other antiplatelet drugs such as GP IIb/IIIa 
receptor inhibitors, crushing or chewing of the ticagrelor tablets (82, 83), or perhaps use of 
pain-relieving drugs other than opioids, which do not reduce the uptake of oral P2Y12-
receptor inhibitors.   
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6 CONCLUSIONS 
The specific conclusions were: 
♦ Testing with the Plateletworks® assay at the start of coronary angiography identified 
the patients with HPR at significantly increased risk of myocardial infarction and 
rehospitalization due to cardiovascular causes within 3 months of the procedure, as 
compared with patients with a normal clopidogrel response. 
 
♦ Clopidogrel-treated patients with low on-treatment platelet reactivity, according to 
platelet function testing with Plateletworks® at the time of intervention, had a 
significantly higher incidence of bleeding defined according to BARC and 
ARMYDABLEEDS <30 days after coronary angiography with and without PCI.                                        
 
♦ NSTEMI patients not receiving opioids have a fast and adequate uptake of ticagrelor 
and onset of platelet inhibition, which was not significantly slower compared with the 
SCAD control group.                                              .   
 
♦ The peripheral opioid antagonist methylnaltrexone did not improve platelet reactivity 
or plasma concentrations of orally administered ticagrelor in STEMI patients 
receiving morphine. The strategy of administering methylnaltrexone to improve the 
uptake of ticagrelor in morphine-treated STEMI patients should not be used in clinical 
practice. 
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